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SUM M ARY
A method has been developed in which intravenous infusions can be given 
and a rte ria l pressure and metabolic balance measured fo r up to 21 days in 
conscious unrestrained rats.
Using the method, a comparison was made o f the d irect vasoconstrictor 
and slow pressor effects of angiotensin II (A ll). Both were related to concurrent 
plasma A ll concentrations. Nine female W istar rats were infused intravenously 
f irs t ly  w ith 5% dextrose fo r 3 days, then A ll at 20ng/kg/min at 2.4mls/day fo r 7 
days and fin a lly  w ith  dextrose fo r  3 days. Nine control rats received dextrose 
throughout. A ll raised mean a rte ria l pressure (MAP) progressively reaching a 
peak on the 7th day, 49.7 mmHg higher than control (p< 0.001). MAP in 
control rats did not change s ign ificantly . The d irect pressor response to A ll 
(30,90 and 270ng/kg/min, each fo r 1 hour) did not change during prolonged A ll 
infusion, although i t  was enhanced 4 hours a fte r stopping prolonged infusion at a 
tim e when MAP was normal. Plasma angiotensin II levels during the 
progressive rise were 6 times those of control rats. In contrast, the pressor 
response to an hourly infusion of A ll at 270ng/kg/min raising plasma levels to  32 
times those of control, was on average 45.3+3 mmHg. This was close to the 
maximum direct e ffe c t since infusion at 810ng/kg/min raised MAP by an 
additional 9.3 mmHg only. Estimates of plasma A ll were confirmed by 
chromatography. Infusion of A ll reduced rather than increased the proportion of 
angiotensin III. Because changes of plasma angiotensin II concentration during 
prolonged infusion were closer to the physiological range of A ll, th is suggests 
tha t the slow pressor e ffe c t o f A ll may be more im portant than the d irect 
e ffe c t in longterm regulation o f MAP.
Saralasin, an e ffec tive  antagonist of A ll, has a rapid ly-acting agonist 
pressor e ffec t. Prolonged infusion of saralasin has been used to assess the role 
o f A ll as a pressor hormone, but i t  is not known i f  saralasin has an additional
slow developing pressor action like angiotensin II. This was tested in B female 
W istar rats. Dextrose was infused intravenously fo r 2 days, followed by 
saralasin at lO ug/kg/m in fo r 4 days and then dextrose fo r 2 days. MAP was 
recorded continuously, Saralasin gradually raised MAP in all rats. A fte r  4 
days, MAP was 22 mmHg higher than in the control period. The diurnal
variation of a rte ria l pressure also increased during saralasin - MAP increased 
during the night between 9 p.m. and 9 a.m. and decreased during the day 
between 9 a.m. and 9 p.m. V a riab ility  o f pressure also increased.
A second group o f rats was infused w ith  A ll at 20ng/kg/min fo r 4 days 
w ith  continuous recording of a rte ria l pressure. A ll, as w e ll as raising MAP 
slowly, also increased va riab ility  and diurnal rhythm of pressure. Saralasin and 
A ll had no e ffec t on food and water intake or on sodium balance. These
findings, together w ith  the structura l s im ilarities between A ll and saralasin,
suggest tha t both peptides are acting by a sim ilar mechanism to raise a rte ria l 
pressure. These properties of saralasin may also compromise interpretation of 
experiments in which the inh ib ito r is given by prolonged infusion to test the role 
of A ll in the maintenance o f MAP.
CHAPTER 1 
REVIEW OF THE LITER ATUR E
1 RENIN AND ANGIOTENSIN
1.1 DISCOVERY
The idea that the kidneys m ight liberate some substance which could
raise a rte ria l pressure was the logical extrapolation of observations made by two 
famous scientists, Richard B right and Charles Brown-Sequard in the 19th
century. I t  was Bright (1836) who f irs t  implicated the kidney in the aetiology
of hypertension when he drew attention to the common association o f renal
disease w ith  a 'hard fu ll pulse' and cardiac hypertrophy. Then in 1856 Brown- 
Sequard proposed tha t organs, in particu lar the kidney, released substances into 
the blood to act at other sites w ith in  the body. Influenced by these ideas, two 
Swedish physiologists, Robert Tigerstedt and Per Bergman, began to  investigate 
the possible endocrine function of the kidney. They prepared crude saline 
extracts of rabbit kidneys which they injected into other rabbits. The extract 
contained an agent which they called renin and which raised a rte ria l pressure. 
Further experiments showed that section of the spinal cord did not abolish the 
pressor e ffe c t and tha t i t  was only from  the cortex that the ex trac t could be 
produced (1898). I t  is interesting, but less well known, that in the same year 
L i von (1898) working in Marseilles, showed that extracts o f various organs, 
including the kidney, raised blood pressure a fte r injection into curarized dogs.
These discoveries remained re la tive ly  unnoticed fo r 40 years un til the 
classical experiments o f H arry G oldblatt in 1934. He showed tha t experimental 
hypertension as sustained as human hypertension could be produced by placing 
adjustable clips on both renal arteries of dogs. Goldblatt suggested tha t a 
humoral mechanism could be raising pressure and this revived interest in a 
pressor substance of renal origin.
A t the end of the 1930's, three d iffe rent groups confirmed Tigerstedt
and Bergman’s original work (Pickering and Prinzmetal 1938; Landis, 
Montgomery and Sparkman 1938; Hessel 1938) and the f irs t assay fo r renin was 
established (Pickering and Prinzm etal 1938). This assay compared the pressor 
e ffects of kidney extracts in the unanaesthetized rabbit w ith  the blood pressure 
increase produced by a standard extract prepared from  normal rabbit kidneys. 
P ickering and Prinzmetal also made the very im portant observation tha t some 
anaesthetic agents, e.g. urethane, ether and nembutal, reduced the pressor e ffe c t 
o f renin considerably.
I t  was then found independently by Braun-Menendez and Page tha t the 
renal pressor extract was itse lf inactive, but was an enzyme releasing the 
pressor substance from  substrate. Working in Cleveland, Page (1939) added 
renin to blood perfusing isolated ears of rabbits. He noticed that i f  
tachyphylaxis occurred in a f irs t  ear, and the same blood was used to  perfuse a 
second ear, that renin had no pressor e ffec t, but tha t the addition o f fresh 
blood restored the response. He concluded that the presence o f renin ac tiva to r 
was necessary fo r a response. Then in 1940, Page and Helmer began looking fo r 
a renin activa tor. They concluded from  the ir studies that the renin ac tiva to r 
was the substrate on which renin acts and began a search fo r products resulting 
from  the interaction of renin and ren in-activator. This search culm inated in 
the extraction of a pressor substance which they called ’angiotonin’. S lightly 
earlier in Argentina, Braun-Menendez and his colleagues were working towards 
the same end. In 1938, Fasciolo, Houssay and Taquini showed tha t when the 
ischaemic kidneys o f dogs, w ith  chronic hypertension were grafted into the neck 
of normal and nephrectomised dogs, tha t a rise in blood pressure of between 30 
and 70 mmHg occurred, while gra fting  the kidneys of normal animals had no 
e ffe c t. They subsequently showed that the venous blood from  these acutely 
Ischaemic kidneys had vasoconstrictor properties. Extracts o f the blood 
contained a pressor substance, which they called ’hypertensin' which was formed 
in v itro  when blood proteins were incubated w ith  renin (Braun-Menendez,
Fasciolo, Le lo ir and Munoz 1939). Braun-Menendez drew the im portant 
conclusion that the production of hypertensin by renin was enzymatic, a process 
which Page had called activa tion . The dual nomenclature, angiotonin and
hypertensin persisted fo r almost 20 years un til in 1958, Braun-Menendez and 
Page issued a jo in t communication in which they compromised calling the 
substance angiotensin.
1.2 PURIFICATION OF ANGIOTENSIN
W ith the discovery of angiotensin and its possible relationship to a rte ria l 
hypertension, scientists turned the ir e ffo rts  to the elucidation o f its chemical 
composition. U n til purifica tion  could be achieved, the compound could not be 
prepared and chemical analytical methods to  determine its  concentration in 
blood and other body flu ids would be unreliable. The f irs t pa rtia lly  successful 
attem pt was that o f P ientl and Page (1945) who attempted purifica tion  by 
form ation o f m eta llic  salts. Their attempts at synthesis, however, were
unsuccessful. The next preparation by Edman (1945) was said to  have been the
purest angiotensin fo r the next 10 years (Bumpus and Smeby 1968). This 
purifica tion  relied on the precip itation w ith  ethanol o f the proteins formed 
during incubation of renin w ith  renin substrate. The pressor frac tion  was 
adsorbed on alumina, the eluate precip itated w ith  n itra n ilic  acid and separation 
achieved by electrodialysis. Ten years la te r, w ith be tte r methods fo r inh ib iting 
angiotensinase a c tiv ity  Skeggs, Marsh, Kahn and Shumway (1954b) and Peart
(1955) obtained pure angiotensin polypeptide. Identifica tion  o f the amino acid 
sequence of angiotensin soon followed. Skeggs, Marsh, Kahn and Shumway 
(1954a) reported the existence of two forms of hypertensin, which they 
designated 'hypertensin I', formed as a result of the action of renin on its 
substrate and 'hypertensin IP formed by the action o f hypertensin converting
enzyme on hypertensin I (Skeggs, Kahn and Shumway 1956). The amino acid 
sequence of this form  of hypertensin I was found to be:-
asp-arg-val-tyr-ileu-his-pro-phe-his-leu
(Skeggs, Marsh, Kahn and Shumway 1955), the result of the reaction of pig renin 
and horse renin-substrate. Meanwhile E llio tt and Peart (1956) had isolated and 
purified hypertensin, produced by the reaction of rabbit renin and ox serum. 
The amino acid sequence of this hypertensin differed only by the presence o f 
valine in place of the f i f th  amino acid, isoleucine. Peart (1956) suggested tha t 
this represented a species difference since Skeggs et al (1955) had used pig 
renin and horse serum. Soon a fte r, Skeggs, Lentz, Kahn, Shumway and Wood
(1956) demonstrated that angiotensin II was an octapeptide formed by the 
removal o f the histidyl-leucine fragm ent from the C -term inal end o f the 
angiotensin I molecule.
The determ ination o f the amino acid sequence o f angiotensin II and 
modern methods of peptide synthesis have allowed the production of synthetic 
angiotensin II, which is now used fo r most investigations where angiotensin II is 
required.
1.3 DESTRUCTION OF ANGIOTENSIN
I t  has long been evident tha t there are substances in blood and tissues 
which are capable of destroying angiotensin (Braun-Menendez, Fasciolo, Le lo ir, 
Munoz 1940). Indeed in 1944, P ientl and Page showed tha t p ro teo lytic  enzymes 
such as carboxy peptidase A, chymotrypsin, trypsin, and pepsin a ll rapid ly 
inactivate angiotensin. The term  'angiotensinase' has been used to  describe 
these enzymes although the ir hnultip lic ity suggests tha t they are non-specific. 
Three main groups of angiotensinases have been described:-
i) Aminopeptidases or Angiotensin 'A ' -  these enzymes which are calcium 
dependent hydrolyse the molecule at the N-term inal bond. Glenner, M cM illan 
and Folk (1962) described such an enzyme in ra t kidney microsomes which they 
named aminopeptidase A, A sim ilar enzyme, found in human plasma and washed 
hemolyzed red cells, was named angiotensinase A (Khairallah, Bum pus, Page and 
Smeby 1963). The la tte r  enzyme was subsequently shown to be two separate 
enzymes (Khairallah and Page 1967), angiotensinase A^, the peptidase specific to
Asn^ A ll and angiotensinase A 2, the peptidase specific to asp^ A IL 
Ü) Endopeptidases, or angiotensinase 'B’-  these hydrolyse the middle of the 
peptide and were discovered by Regoli, R iniker and Brunner (1963). A sim ilar 
plasma endopeptidase, inhibited by diisopropyl-fluorophosphate (DFP) was 
described by Khairallah and Page (1967).
i i i )  Carboxypeptidases or angiotensinase 'C  - these hydrolyse the C -term inal 
bond of angiotensin II. Lentz, Skeggs, Woods, Kahn, Shumway (1956) showed 
tha t pancreatic carboxypeptidase A released phenylalanine from  A IL Evidence 
of carboxypeptidase a c tiv ity  has been found in aqueous extracts o f rabbit live r 
(Johnson and Ryan 1968).
Although aminopeptidases and endopeptîdases are present in plasma and 
serum, degradation of angiotensin II in blood is now known to be a slow process 
of minor significance compared w ith  the rapid catabolism of the peptide in 
tissue vascular beds (Hodge, Ng and Vane 1967; Bakhle, Reynard, and Vane 
1969, Ng and Vane 1968).
1.3:1 Fate of angiotensin in the body.
Angiotensin II has a very short biological h a lf- life , according to  early 
estimates, about 10 minutes (Corcoran, Kholstaedt, Page, 1941). However, as 
pure angiotensin and better means of detection became available, estimates of 
the h a lf- life  became very much shorter, more recent estimates by 
radioimmunoassay being of the order o f one minute (Cain, C a tt, Coghlan and 
Blair-W est 1970). This accords w ith  the brie f pressor response fo llow ing 
intravenous injection of angiotensin II (Peart 1955). In order to  ascertain the 
various vascular beds responsible fo r the removal o f angiotensin II, Hodge, Ng 
and Vane (1967) infused angiotensin II and showed tha t the live r, head, kidneys 
and hindquarters removed up to 75% of the a c tiv ity  in one circula tion, while the 
lungs removed none. Use o f isotopically labelled angiotensin (Bumpus, Smeby, 
Page and Khairallah 1964) to determine the regional d istribution of angiotensin, 
showed that there was a high concentration in the uterus, adrenals and kidneys.
A fte r 30 minutes, the uterine concentration had dropped, the brain concentration 
had risen and the kidneys and adrenals retained substantial a c tiv ity . One 
possibility was tha t the more prolonged e ffects of angiotensin were only re levant 
to the kidneys, adrenals and the central nervous system. But d if f ic u lty  
in terpre ting  these experiments is tha t the label may become separated from  the 
original peptides or from  the peptide fragments a fte r enzymatic degradation.
1.4 ANGIOTENSIN II, A BLOOD BORNE OR LOCAL TISSUE HORMONE?
In vertebrate evolution, some of the earliest hormones were local tissue 
hormones. Later, in evolution, when the circulation developed, these hormones 
were spilled into the blood to  produce effects at a distance. The renin- 
angiotensin II system may have developed in this way (Brown, Fraser, Lever and 
Robertson 1968). Indeed there is some evidence tha t angiotensin II may be 
generated by renin w ith in  the blood vessel walls and w ith in  the tissues o f the 
brain and the kidney as w ell as in the circulation (Malik and N as jle tti 1976; 
Swales 1979).
Vessel wall preparations of the aorta and large arteries have been shown 
to contain ren in-like a c tiv ity  which generates angiotensin I at a physiological 
pH. I f  such a c tiv ity  re flects  equivalent a c tiv ity  at the resistance vessel 
receptor site and i f  substrate and converting enzyme were also present, i t  is 
possible tha t high concentrations of angiotensin II would be formed loca lly  and 
could thus modulate both blood pressure and the pressor response to  injected 
angiotensin II (Swales 1979).
Another site where local form ation o f angiotensin II  could exert an 
influence on blood pressure is in the brain. Renin-like a c tiv ity  has been 
detected in every part of the brain examined (Ganten, Hutchinson, Schelling, 
Ganten and Fischer 1976), although i t  has been identified  by one group as 
cathepsin D (Reid 1977). Thus there is considerable debate as to whether 
angiotensin I or II is generated in the brain in vivo (Reid 1977, Ganong 1977, 
Ganten 1978) and whether i t  plays a role in the pathogenesis o f hypertension.
A considerable amount of evidence now suggests tha t angiotensin II is 
generated loca lly  w ith in  the kidney and can influence renal function under 
conditions of sodium and water res tric tion  (Levens, Peach and Carey 1981).
There exists the possibility then that renin and angiotensin act in the 
body as local tissue hormones. I t  is im portant, however, to  note tha t although 
many of the tissues studied contain enzymes which produce angiotensin I when 
incubated w ith  naturally-occurring or synthetic substrate, i t  does not fo llow  th a t 
these enzymes have a physiological ro le in the form ation of angiotensin and in 
the regulation of blood pressure. In the sections which fo llow  I shall consider 
evidence that angiotensin I I  is also a blood borne hormone.
1.5 PHARMACOLOGICAL AND PHYSIOLOGICAL EFFECTS
OF ANGIOTENSIN II.
Angiotensin II has many actions. Although the ir existence is not 
disputed, there is considerable controversy as to whether they are 
pharmacological curiosities or physiological phenomena. Demonstration o f a 
pharmacological e ffe c t does not necessarily reveal a physiological mechanism. I 
have tried  to distinguish the two forms of experiment. The discussion below 
concerns angiotensin II, its pressor actions, its nervous effects and its  
interrelationships w ith  sodium, blood pressure and aldosterone,
1.5:1 Pressor action
The immediate pressor e ffec t o f renin, subsequently shown to be due to  
form ation of angiotensin II was the earliest to be demonstrated (Tigerstedt and 
Bergman 1898) and remains the most studied of its  actions (DeBono, Lee, 
M ottram , Pickering, Brown, Keen, Peart and Sanderson 1963). DeBono et al 
(1963) showed that angiotensin II was approximately 6-8 tim es more potent as a 
pressor agent than noradrenaline on a weight basis and 40-60 times stronger on 
a molar basis.
In in tac t animals, including man, the characteristic response to an 
intravenous in jection o f angiotensin II is a sharp rise in systemic a rte ria l
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pressure w ith in  20 to 30 seconds, which reaches a peak in 1-2 minutes and 
returns to normal w ith in  3 minutes. The height of the response is dose- 
dependent. Evidence that tachyphylaxis to angiotensin II could occur was 
provided by Bock and Gross (1961) who demonstrated tha t large doses o f 
angiotensin in dogs diminished or abolished the pressor response to subsequent 
injections of angiotensin II. I t  is like ly  tha t tachyphylaxis is due to occupation 
o f receptors by angiotensin. This has been supported by the observation 
(Khairallah, Page, Bumpus, and Turker 1966; Bohr and Uchida 1967; W alter and 
Bassenge 1969) tha t treatm ent of tissue showing tachyphylaxis to angiotensin II 
w ith  a solution containing angiotensinase ac tiv ity , or w ith  Dowex resin, 
diminishes the tachyphylaxis.
As w ell as its d irect vasoconstrictor pressor e ffe c t, angiotensin II raises 
a rte ria l pressure gradually when given in low dose fo r a prolonged period. This 
was f irs t shown by Dickinson and Lawrence in 1963. I t  is the main subject o f 
my thesis and w ill be discussed in greater detail la te r.
Mechanism of the d irect vasoconstrictor action of angiotensin II 
The contractile  apparatus in vascular smooth muscle is activated by a rise in 
the cytoplasmic contraction o f ionized calcium. Thus, a vasoactive substance, 
like  angiotensin II, in itia tes contraction by its ab ility  to raise in trace llu la r 
ionized calcium (Daniels and Kvjan 1981). Calcium can enter the ce ll through 
two types of ion channels in the membrane, (1) potential-operated channels 
which admit calcium when they are caused to open by depolarization and (2) 
receptor-operated channels (ROC's) associated w ith  the receptors fo r a stim ulant 
substance. These receptor-operated channels appear to  be a separate and 
d istinct population from  the ion channels although sometimes activation o f a 
receptor may a ffec t the opening o f potential sensitive channels (Bolton 1979). 
Opening of either channels increases the permeability of the membrane to  
calcium which triggers contraction, possibly by releasing more calcium from  
bound sites on the side of the membrane and on the sarcoplasmic re ticu lum
(Bolton 1979). Thus, an agonist may a ffec t calcium movements by 
depolarization and/or occupation of receptors both of which may a ffec t calcium 
binding or transport by in terna l membranes (Daniels and Kwan 1981; Benham and 
Bolton 1981).
Angiotensin II has been shown to cause depolarization and contraction o f 
spiral strips of carotid arteries of sheep (Keatinge 1966). The peptide also 
contracts the same arteries in the presence of depolarizing concentrations of 
potassium, but w ithout any detectable e lectrica l changes, suggesting that the 
action of angiotensin II is, at least in part, independent of changes in membrane 
potential (Keatinge, 1966).
A combination of angiotensin II w ith  its receptor thus causes an increase 
in the permeability of the membrane to calcium. The movement o f calcium 
and possibly sodium across the membrane into the cell is probably responsible 
fo r the depolarization sometimes seen in certain vascular smooth muscles 
exposed to angiotensin II, As w ell as movement of extracellu lar calcium into 
the cell, angiotensin II may also displace calcium by receptor activation from  
bound sites w ith in  the cell which explain its ab ility  to produce contraction 
w ithout depolarization (Bolton 1979). The site of this bound calcium may be 
the plasma membrane, mitochondrion or endoplasmic reticulum  as well as 
calcium bound to the receptor. Angiotensin II has been shown to  increase the 
e fflux  o f ^^Ca from  a preparation o f vesicular cell fragments of rabbit aorta 
(Baudouin, Meyer, Fermandjian and Morgat 1972). The vesicular fragments 
were absent of m itochondrial contamination since no cytochrome c. oxidase 
a c tiv ity  was detected, suggesting the cell membrane and endoplasmic reticu lum  
are the only im portant internal stores o f calcium.
The mechanism whereby activation of receptors by angiotensin II causes 
release o f internal bound calcium is not yet clear, but could involve either a 
calcium induced release of bound calcium or biochemical changes w ith in the 
cell, e.g. changes in cyc lic  nucleotide levels. Volicer and Hynie (1971) showed
tha t vasoconstriction induced by angiotensin II in ra t aorta is associated w ith  
decreased adenylate cyclase a c tiv ity  while some recent work (V es el y 1981) has 
shown tha t angiotensin II in physiological concentrations enhanced guanylate 
cyclase a c tiv ity  in ra t aorta. These biochemical e ffects, however, do not occur 
w ith  a tim e course comparable to  other drug effects and i t  therefore seems 
unlikely tha t they are involved in the pathway between receptor activation and 
contraction of the smooth muscle cell (Bolton 1979).
1,5:2 E ffects of angiotensin II mediated by the nervous system.
The idea tha t there might be a link between angiotensin II and the 
nervous system came from  the early work of Tigerstedt and Bergman (1898) who 
concluded that the principal mechanism of renin's pressor action was neural, 
involving peripheral components of the autonomic nervous system.
The subject lay dormant fo r several years. Then considerable evidence 
appeared showing tha t angiotensin II acted on the central and peripheral nervous 
system at several levels.
1) Central nervous system.
a) Pressor e ffects. In the early 1960's cross-perfusion experiments in
dogs indicated tha t in jection o f A ll into the circulation o f the donor or into the 
a rte ria l supply to the head o f the recip ient, resulted in a systemic pressor 
response in the recipient, although the la tte r was connected to its head by the 
spinal cord only (Bickerton and Buckley 1961). This cen tra lly  mediated pressor 
response was inhibited by piperoxan, a sympatholytic agent. In these early 
experiments, the doses of angiotensin II u tilized were large and unphysiological. 
Subsequent investigations, however, have shown that doses of peptide nearer the 
physiological range of A ll induce a centra lly mediated pressor response: 
adm inistration of A ll into the vertebral circulation of conscious rabbits, in doses 
. which had no e ffec t i f  administered intravenously, resulted in an increase in 
peripheral blood pressure (Yu and Dickinson 1965). An increase in blood 
pressure induced by angiotensin adminstration centra lly  has been confirmed in
the dog (Lowe and Scroop 1969), cat (Severs, Daniels, Smookler, Kinnard, 
Buckley 1966), and ra t (Fink, Haywood, Bryan, Packwood and Brody 1980) and 
the effects observed are mediated mainly by increased e ffe ren t sympathetic 
a c tiv ity  and partly by w ithdrawal o f parasympathetic discharge. The rise in 
pressure is due p rim arily  to  increases in peripheral resistance, although 
sometimes increased cardiac output contributes (depending on the species) 
(Severs et al 1966; Lowe and Scroop, 1969)
Various neural ablation and recording procedures were then used to 
elucidate the site at which angiotensin exerts its  pressor e ffects. These 
revealed tha t the area postrema, a medullary circum ventricu lar organ, is a like ly  
site of action o f A ll in the dog (Gildenberg, Ferrario and McCubbin 1973; Joy 
and Lowe 1970), and rabbit (Yu and Dickinson 1971), The area postrema, a 
zone where the blood brain barrier is defic ient (Wislocki and Putman 1924), has 
in tim ate  connections w ith  the nucleus of the so litary tra c t (Merest 1967) part o f 
the vasomotor centre, the la tte r also receiving fibres from  the glossopharyngeal 
nerve and carotid sinus nerve (Gabriel and Belter 1970). The interconnection 
has led to the suggestion tha t angiotensin may act cen tra lly  to  modulate the 
baroreceptor re flex (Sweet and Brody 1970) and there is some supportive 
evidence fo r this (Fukiyama 1973; Goldstein, H e itz , Schaffer and Brody 1974, 
Marker, Miles and Scroop, 1980). Some recent work in the ra t (Haywood, F ink, 
Buggy, Phillips and Brody 1980; Fink e t al 1980) has im plicated periventricu lar 
structures surrounding the 3rd- ventric le  rather than the area postrema the 
centra l site fo r pressor action o f blood-borne angiotensin in the ra t.
b) Dipsoqenic and feeding responses. The administration o f angiotensin II into 
the central nervous system stimulates drinking in several species (Epstein, 
Fitzsimons and Rolls 1970; Rtzsim ons, Kucharczyk and Richards 1978). The 
area of the brain most sensitive is the subfornical organ (Simpson and 
Routtenberg 1973), application of 0.1 ng angiotensin II to  th is area e lic iting  a 
drinking response. This amount o f angiotensin II, however, is large and would
produce a high concentration diluted in a small volume. I t  is therefore unlikely 
to be physiological. However, as w ell as d irect injection o f angiotensin II into 
the brain, systemic infusion in physiological amounts does induce drinking in the 
water replete animal (Trippodo, McCaa and Guyton 1976; Fitzsimons et al 
1978).
Angiotensin II, as well as stim ulating drinking, also acts d irectly  on the 
central nervous system to suppress feeding (Epstein et al 1970; McFarland and 
Rolls 1972). La ter studies, however, (Rolls and McFarland 1973) showed tha t 
the suppression of feeding depends on the th irs t inducing property of the 
substance, i.e. angiotensin does not act d irec tly  on feeding systems but ra ther 
acts on the th irs t mechanisms which, in turn, suppress feeding,
c) E ffects on the p itu ita ry  Increased circulating levels of angiotensin have 
been shown to increase the plasma concentration of arginine vasopressin (Bonjour 
and Malvin 1970; Ke il, Summy-Long and Severs 1975; Mouw, Bonjour, Malvin and 
Vender 1971). Some investigators, however, have been unable to observe such 
an increase (Claybaugh, Share and Shimizu 1972; Shade end Share 1975) and so 
there exists controversy as to whether angiotensin II is of physiological 
importance in the control of vasopressin secretion. Padfield and Morton (1977) 
measured c ircula ting levels o f arginine vasopressin and corresponding angiotensin 
II levels in physiological states in man and during infusions of angiotensin II. 
Angiotensin II was found to stim ulate secretion o f AVP but only a t 
supraphysiological concentrations. Cowley, Switzer and Skelton (1981) infused 
angiotensin II at physiological rates into dogs fo r 7 days and concluded tha t 
c ircu la ting  angiotensin II was not Involved in the longterm  control o f AVP 
secretion.
2) Action of angiotensin II on the sympathetic nervous system.
In the early 1960’s, evidence accumulated suggesting that some o f the 
e ffects of angiotensin II result from  an action on the autonomic nervous system. 
Zimmerman (1962) showed tha t sympathectomy greatly reduced the response to
in tra -a rte ria l angiotensin injected in to  an isolated hind-limb preparation. 
Angiotensin II was also found to induce ganglionic stim ulation (Kaneko, McCubbin 
and Page 1961) and fa c ilita te  responses to nerve stim ulation and drugs or 
reflexes which evoked the release of noradrenaline (McCubbin and Page 1963; 
Kaneko, Takeda, Koujl and Ueda 1966). P retreatm ent w ith  reserpine, which
depletes catecholamines, diminished the e ffec t of angiotensin II on blood 
pressure (Baum 1963). This fa c ilita tio n  of angiotensin II was partly  thought to
be due to a d irect action on the e ffec to r, leading to an increase of the ir 
sensitiv ity to noradrenaline and there exists some evidence fo r this (Zimmerman 
1978). However, in addition to this postsynaptic component, angiotensin has 
presynaptic actions which increase the release o f transm itte r noradrenaline. 
Evidence fo r this was firs t presented by Zimmerman and Whitmore (1967) who 
showed that angiotensin augments the overflow of noradrenaline evoked by 
sympathetic nerve stim ulation. There has been considerable controversy 
concerning the mechanism of this e ffe c t, the main postulates being tha t 
angiotensin II inhibits neuronal uptake of noradrenaline (Khairallah 1972) and tha t 
i t  enhances the average release of transm itte r per impulse (Benelli, Bella and 
Gandini 1964). I t  is now accepted tha t the la tte r is o f greater importance than 
the form er (Starke 1977). The mechanism of this peripheral adrenergic 
fa c ilita tio n  is not known, although i t  is suggested tha t angiotensin can a ffe c t 
the neuronal membrane, possibly resulting in a change of calcium flux  
(Zimmerman 1981). Zimmerman (1981) in a recent review discusses the
possible importance o f central and peripheral adrenergic fa c ilita tio n  in certa in
pathophysiological conditions.
1.5:3 Aldosterone stim ulation
The f irs t  evidence to  suggest a relationship between the renin-angiotensin 
system and aldosterone was histological. Deane and Masson (1951) showed tha t 
injections o f pa rtia lly  purified solutions o f renin caused enlargement of the zona 
glomerulosa of the adrenal cortex in rats. Then in the la te  1950’s there was
the speculation o f Gross (1958) followed by a series of elegant studies in several 
laboratories in the 1960’s showing the existence of an aldosterone stim ulating
hormone of renal origin, probably renin (Davis, Carpenter, Ayers, Holman and
Bahn 1961) and tha t injected angiotensin II increased aldosterone (Laragh, 
Angers, K e lly  and Lieberman 1960; Biron, Koiw, Nowaczynski, B rou ille t end 
Genest 1961). There is now l i t t le  doubt that angiotensin II stimulates
aldosterone synthesis by the adrenal cortex and is probably the major fa c to r 
responsible fo r the control of aldosterone secretion in response to  changes in 
sodium balance (Fraser, Brown, Lever, Mason and Robertson 1979; Brown,
Casals-Stenzel, Gumming, Davies; Fraser, Lever, Morton, Semple, Tree and 
Robertson 1979). The heptapeptide, des-Asp^-anglotensin II may be im portant in 
stim ulating aldosterone in the ra t (Semple and Morton 1976).
1,5:4 Renal effects.
Infusion of angiotensin at low doses produces sodium and w ater re tention 
(Brown and Peart 1961, 1962; Malvin and Vander 1967; Waugh 1972). This may 
be due to stim ulation of renal tubular sodium reabsorption as w ell as to  the 
haemodynamic changes produced by angiotensin II (Johnson and M alvin 1977). 
Studies w ith  the com petitive antagonist Sar^ Ile^ angiotensin II and the 
converting enzyme inh ib ito r, 5Q 14225 in sodium depleted dogs have suggested 
tha t the d irect e ffec t of angiotensin may be more im portant than the changes 
in aldosterone secretion in regulating renal haemodynamics and e lec tro ly te  
excretion during chronic sodium deprivation (Hall, Guyton, Smith and Coleman 
1979, H all, Guyton, Smith and Coleman 1980).
1.6 INHIBITORS OF THE RENIN ANGIOTENSIN SYSTEM
Major advances in our understanding o f the ro le  o f the renin-angiotensin 
system in blood pressure control and salt and water homeostasis have been made 
as a result of the iden tifica tion  and synthesis o f specific  inhib itors o f renin, 
converting enzyme and angiotensin II.
1.6:1 Renin inhibitors
As early as 1953, Wakerlin, Bird, Brennan, Frank, Kremen, Kuperman and 
Skom (1953) showed tha t immunization of dogs w ith  hog kidney extracts 
containing renin was successful in preventing the development o f renal 
hypertension. Although objections were raised that the extracts were fa r from  
pure and could react w ith  other renal components, this work in itia ted  the search 
fo r substances which m ight inh ib it the enzyme. Improved methods have 
enabled complete purifica tion  o f hog (Corvol, Devaux, Ito , Sicard, Duclox and 
Menard 1977), human (Galen, Devaux, Guyenne, Menard and Corvol 1979) and 
dog (Dzau, Slater and Haber 1979) kidney renin, and the la tte r  has been used to  
raise specific antibodies fo r use as physiological probes (Haber 1980). Some
work in the dog w ith  antibody Fab fragments, which avoid problems w ith
immune complexes or complement activation, looks promising (Haber 1980).
Compared w ith  other acid proteases, renin acts on a re la tive ly  narrow 
region of substrate. This property o f renin has enabled the synthesis o f 
octapeptides containing the leucyl-leucine bond. These act as com petitive renin 
antagonists (Haber 1980). Although this work on renin Inhibitors is in its  
prelim inary stages, they should prove exciting tools fo r the fu tu re . I shall 
describe an experiment w ith  a new renin inhib itor.
1.6:2 Inh ib itory angiotensin II analogues
The recognition o f the c ritica l importance o f position 8 in the biological 
a c tiv ity  of angiotensin II was a key step in the development o f angiotensin II 
blocking agents (Khairallah, Toth and Bum pus 1970). Khairallah et al (1970) 
observed tha t A la^ -A ng II, given in concentrations >500 ng/m l specifica lly  
blocked the contractile  response o f angiotensin on the isolated guinea-pig ileum. 
Various amino acids have been substituted in this position -  alanine, 
phenylalanine, isoleucine, threonine and O-methylthreonine. The introduction of 
sarcosine into position 1 created a much more e ffec tive  inh ib ito ry  peptide (Pals,
Masucci, Sipos, Denning 1971a) by preventing the degradation o f the analogue by
aminopeptidase A and resulting in a substantial increase in the h a lf- life  (Bumpus
1977), These analogues, however, a ll contain a certain degree of agonist 
a c tiv ity , sarcosine^-isoleucine® A ll having more agonist a c tiv ity  than sarcosine^- 
alanine^ A ll and sarcosine^-threonine^ A ll analogue having less (Bumpus 1977; 
Saltman, Fredlund and C a tt 1976). This agonist a c tiv ity  was im portant in one
of my experiments and I discuss i t  in more detail la te r,
Sar^, Ala^ angiotensin II has been used extensively in man and animals. 
A hypotensive e ffe c t has been consistently observed in hypertensive patients 
w ith  raised plasma levels of renin and angiotensin II (Brown, Brown, Fraser, 
Lever, Morton, Robertson, Rosei and Trust 1976), although patients w ith  low 
plasma renin levels may exhib it a m ild pressor response to the analogue, a 
result o f its  partia l agonist properties (Case, Wallace, Keim , Sealey and Laragh
1976), The reduction of blood pressure w ith  saralasin is re lated to the plasma
concentration of angiotensin II before its  infusion (Brown et al 1976). In 
addition, sarcosine^, alanine^ angiotensin II produces an in it ia l transient pressor 
response which is associated w ith  a rise in the plasma concentration of 
noradrenaline (McGrath, Ledingham and Benedict 1977).
1.6:3 Converting enzyme inhibitors
Bakhle (1968) f irs t  observed tha t bradykinin-potentiating fac to r, a 
m ixture of peptides from  the venom of the South American p it viper, Bothrops 
jaracara, inhibited the conversion of angiotensin I by particles of canine lung. 
Several of these peptides were synthesised (Engel, Schaeffer, Gold, and Rubin 
1972), However, many subsequent studies have been carried out w ith  a proline* 
derivative 'captopril* (SQ 14225). This compound is an e ffec tive
antihypertensive agent in certain c lin ica l and experimental situations. However, 
a ll converting enzyme inhibitors su ffe r from  one grave disadvantage as sc ien tific  
tools. This is the ir doubtful specific ity ; the contribution o f bradykinin 
potentiation to the blood pressure fa ll produced by converting enzyme inh ib ition 
is uncertain. Thurston and Swales (1978) showed tha t converting enzyme 
inh ib ito r produced a fu rthe r blood pressure fa ll in animals pretreated w ith
saralasin to block the renin-angiotensin system, thus suggesting an additional 
vasodepressor mechanism.
1.7 THE SLOW PRESSOR EFFECT OF ANGIOTENSIN II
As mentioned previously, angiotensin II infused at subpressor doses into 
animals fo r periods of days, results in a slow rise of pressure. This action was 
f irs t  demonstrated by Dickinson and Lawrence (1963) in the rabbit. Infusion of 
angiotensin II at doses between 3 and 10 ng/kg/m ln fo r 4 days raised a rte ria l 
pressure slowly by 5-30 mmHg. Dickinson and Yu la te r showed tha t
adrenalectomy did not prevent the hypertension, but tha t a varie ty o f 
sympathetic nervous system blocking agents did attenuate or abolish the response 
(Dickinson and Yu 1967a; Yu and Dickinson 1971), thus im plicating the nervous 
system in the mechanism of the slow e ffec t. Since then the slow e ffe c t has 
been studied in a varie ty o f species,
Koletsky, Rivera-Velez and Pritchard (1965) produced sustained 
hypertension by infusing angiotensin II at 10 ng/kg/m in in te rm itte n tly  (12 
hours/day) into rats fo r 5 days. Three months la te r, the rats had developed 
hypertension. McCubbin, Demeura, Page and Olmsted (1965) were f irs t  to  
demonstrate the e ffec t in the dog. They infused angiotensin II a t lO pg/kg/day 
into  dogs fo r 2 weeks and showed an increase of 45 mmHg in a rte ria l pressure. 
A rte ria l pressure showed great la b ility  during the infusion and the ra te  of fa ll 
of pressure on stopping the infusion was dependent on the duration of the 
infusion, being slower w ith  longer infusions. Studies in dogs have indicated 
tha t the magnitude of the rise of pressure during a continuous infusion o f 
angiotensin II at 5ng/kg/min is re lated to  the sodium intake of the animals, a 
larger intake producing a greater rise of pressure (Cowley and McCaa 1976; 
DeClue, Cowley, Coleman, McCaa and Guyton 1976) and tha t th is form  o f 
hypertension can be prevented by d ietary salt restric tion  (Cowley and McCaa 
1976). Plasma aldosterone levels, however, were not elevated unless the ra te
of A ll infusion was increased to 15-23ng/kg/min. These results suggest tha t the
rise of a rte ria l pressure occurs independently of changes in aldosterone 
secretion. Bean, Brown, Casals-Stenzel, Fraser, Lever, M ilia r, Morton, Petch, 
Riegger, Robertson and Tree (1979), infusing dogs w ith  A ll at 3ng/kg/min fo r 2 
weeks, also concluded tha t a persistent increase in aldosterone was not 
im portant. Systemic a rte ria l pressure in these animals was increased by 26 
mmHg by the end of the infusion, which also caused a sh ift in the relationship 
o f plasma angiotensin II and a rte ria l pressure, so tha t a given plasma 
concentration of the peptide maintained a higher pressure.
The slow pressor e ffe c t has also been observed in man. Ames, 
Borkowski, Sicinski and Laragh (1965) maintained a small, but constant increase 
of blood pressure w ith  a decreasing ra te of angiotensin infusion. Infusion of 
A ll constantly at 2ng/kg/min fo r 66 hours into man raised blood pressure by 
15/4 mmHg (Oelkers, Schoneshofer, Schultze, Brown, Fraser, Morton, Lever and 
Robertson 1975),
The idea tha t the slow pressor e ffec t m ight be im portant in the 
pathogenesis of hypertension was f irs t envisaged by Dickinson and Lawrence 
(1963). They suggested tha t angiotensin m ight specifica lly constrict the cerebral 
vessels end increase the cerebrovascular resistance, thus a ltering the in trins ic  
a c tiv ity  of the medullary vasoconstrictor centre. I propose to discuss the 
possible role of the slow pressor e ffe c t in the pathogenesis o f chronic renal 
hypertension la te r in this thesis.
1.8 PURPOSE OF THE PRESENT STUDY
My main purpose^ was to study the slow pressor e ffe c t o f angiotensin II
in more deta il. The ra t was chosen because i t  is small, cheap and robust and 
because i t  is easier to  make hypertensive by renal artery, clipping and in jection
of DOCA than are dogs and rabbits. I t  was therefore necessary to  develop a
technique whereby continuous intravenous infusion could be given and blood 
pressure could be recorded continuously fo r periods of up to 3 weeks in 
conscious unrestrained animals. Although Koletsky et al (1965) had produced
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sustained hypertension w ith  in te rm itte n t infusions of angiotensin II, blood 
pressure was not recorded in the early stages of infusion and the infusions were 
not continuous.
Because there were no techniques fo r continuous recording and infusion, 
i t  was my firs t task to develop them.
I f  the slow e ffec t occured in the ra t, I proposed to determine its 
magnitude, compare i t  w ith  the d irect vasoconstrictor e ffe c t in the ra t and 
search fo r a mechanism. F ina lly, i f  possible, I hoped to  determine the 
contribution of the slow e ffe c t to the pathogenesis of chronic renal 
hypertension. In the event, the slow pressor e ffec t was more marked than I 
had expected and was associated w ith  increased diurnal variation o f a rte ria l 
pressure. Also during an early stage of the experiment on renal hypertension I 
discovered an interesting and previously unrecognised action of saralasin. This 
drew my attention away from  the fina l objective.
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CHAPTER 2 
METHODS.
My main technical problem was to develop a method capable o f giving 
continuous intravenous infusions in the conscious unrestrained ra t, and at the 
same tim e to measure a rte ria l pressure continuously and estimate metabolic 
balance, a ll fo r periods of up to 21 days, I had most d if f ic u lty  w ith  the 
a rte ria l and venous catheters but eventually succeeded w ith  them positioned in 
the aorta and in fe rio r vena cava. These and the earlier unsuccessful techniques 
are described,
2.1 RATS AND THEIR CAGES.
Throughout all of the studies to be described, female rats from  an inbred 
Wistar strain were used. They weighed 18Qg to 220g and were supplied by Olac 
L td , (Sussex). Female rats in this weight range are approaching the plateau of 
the ir growth curve and ra re ly  gain more than 5g in body weight in a week. 
This is im portant in longterm studies using catheters fo r blood pressure 
measurement, since the size and f i t  of catheters is c r itica l to  the ir function and 
patency.
A t f irs t  rats were housed in groups of four in plastic cages w ith
aluminium lids in an animal house o f constant temperature (1B-22°C) and 
lighting (12 hour light/darkness cycle). Rats studied in the conscious state were 
transfered to the laboratory in which the measurements were to  be made at
least one week before the s ta rt o f the experiment.
Following catheterisatlon they were housed individually in plastic cages 
w ith  aluminium lids, designed to minimise damage to  catheters. A fte r  a period 
o f recovery, they were placed singly in metabolic cages fo r acclim atiza tion.
They remained in the metabolic cages fo r the duration o f the experiment. The 
laboratory was kept at a temperature of 20-25°C.
2.2 CATHETERÎSATÎON.
A rte ria l and venous catheters were needed fo r blood pressure recording 
and intravenous infusion.
2.2:1 Carotid artery and jugular vein catheters.
Prelim inary studies were carried out using the carotid artery and jugular 
vein fo r catheterisation. Two types o f a rte ria l catheters were tested, one type 
of venous catheter.
i) Construction of carotid and jugular catheters. The form  of the three 
catheters is illustra ted in Figure 2.1. Their construction is detailed in Appendix 
1.
ii)  Im plantation of carotid artery and jugular vein catheters. Catheters 
were fille d  w ith  heparin (1000 units/m l) and the end plugged w ith  1 cm of 
stainless steel w ire (0.7 mm diameter in type 1 carotid catheter, 0.9 mm in 
type 2 carotid catheters and 0.5mm in jugular catheters) which had been 
care fu lly  rounded at one end to prevent damage to the catheters. Plugs and 
catheters were sterilised overnight in a 5% hibitane/alcohol solution. 
Instruments used fo r the operative technique were sterilised by boiling.
Rats were anaesthetised w ith  ether. Before the operation both the fro n t 
and back of the neck were shaved and cleaned w ith 5% hibitane/alcohol solution. 
A 1-2 cm longitudinal incision was made at the fron t of the neck. The le f t  
carotid artery was freed by blunt dissection. Three pieces of thread (4/0 silk) 
were passed beneath the artery. The most distal thread from  the heart was 
tied  in a tig h t knot, the other threads tied loosely. Gentle trac tion  was 
exerted on the lower tie  by a rte ry forceps to stop the blood flow . The tip  o f 
the catheter was trimmed to form  a blunt bevel 2,0 to  2.5 cm from  the jo in 
w ith  the tygon tubing. Using small scissors an incision was made in the artery 
between the two sutures. The catheter was then inserted, moved care fu lly  up 
to the lower tie  and tied  into place w ith  the loose thread. The lower tie  was 
released and the catheter pushed gently into the artery un til the whole of the
Carotid Catheter T ype 1 
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lying within the carotid artery
Carotid Catheter T ype 2
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of transparent vinyl tubing was used instead of tygon and 3.5 cm 
length of polythene tubing (0. 3BmmID, 1.09mm OD)
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Figure 2 .1  Carotid artery  and jugular vein catheters
2.5 cm polythene tip  lay w ith in  the vessel. A ll of the threads were tied  f irm ly  
round the catheter to hold i t  in place. The ends of the sutures were sewn into 
the underlying muscles and tied tig h tly  again.
The righ t jugular vein was exposed. Three lengths of thread were then 
passed under the vein and tied loosely. Gentle trac tion  was applied to  the 
upper and lower ties by means of a rte ry forceps and an incision was made in 
the vein. The end o f the catheter was trim m ed to form  a b lunt bevel and then 
inserted 2.5 cm into the vein. I t  was tied firm ly  in place and then into the 
underlying muscle as fo r the carotid catheter. Both catheters were passed 
subcutaneously to the back of the neck by means of a hollow needle. The skin 
was sutured and rats received am picillin  (125 mg) subcutaneously.
i i i)  Performance of carotid and jugular catheters. C arotid and jugular
catheters were not a success fo r longterm recording and infusion. There were 
three main problems.
a) Removal o f venous catheters. Jugular catheters were frequently pulled 
out by tangling in bars of the cage beneath the food hopper. This was avoided 
by a m etal barrier which prevented access to  this part of the cage.
b) Occlusion of arte ria l catheters. In order to  m aintain patency both 
a rte ria l and venous catheters were flushed w ith  heparin. Blood was allowed to  
flow  back and the deadspace of the a rte ria l catheter was fille d  w ith  fresh 
heparin (1000 units/m l) daily. The venous catheter was flushed w ith  0.04 ml of 
heparin (1000 units/m l) so that the ra t received system ically 40 units of 
heparin/day. In spite' o f this, carotid type 1 catheters remained patent fo r 
-only 5 days on average a fte r im plantation while type 2 catheters remained 
patent fo r only 3 days on average. Pulse pressure was reduced, sometimes 
gradually, during this tim e.
To prolong patency, d iffe ren t concentrations of heparin were tested and 
the number of daily flushings increased. In one experiment, a rte ria l catheters 
were f ille d  w ith  5000 units/m l of heparin instead of 1000 un its/m l. In another,
catheters were flushed three times daily instead of once. The firs t increased 
the duration of patency to 7 days on average fo r both types of arte ria l 
catheters, but also increased the incidence of haematomas. Interestingly, w ith  
the second, the catheters became blocked earlier rather than later,
c) Macroscopic kidney damage. The th ird  and perhaps most serious problem 
was the e ffe c t o f carotid a rtery catheters on the kidney. Postmortem
examination showed tha t in some rats there was macroscopic damage to the 
kidneys, in particu lar small areas of in fa rc tion . In 9 rats implanted w ith  type 1 
carotid catheters, 3 showed damage to  the kidneys; 2 o f 7 rats bearing type 2 
carotid catheters had damaged kidneys, but 6 rats bearing jugular catheters only 
did not have damaged kidneys. Thus, the arte ria l catheter was sometimes 
damaging the kidneys. D aily flushing may have dislodged clots formed at the 
catheter tip .
My general conclusion from  this experiment was tha t carotid and jugular 
catheters may be suitable fo r short-term  experiments (a possibility I have not 
tested) but they were not suitable fo r the longterm infusion studies I had in 
mind.
2.2:2 A o rtic  catheterisation
A tten tion  now turned to  aortic catheters. The method was modified from  
the technique o f Weeks and Jones (1960) (Browning, Ledingham and Felling 
1970).
i) Construction of catheters. The catheter consisted of 4 pieces o f 
polythene, A,B,C and D welded together by heating and had 3 anchor points 
used to secure the catheter to the tissues by sutures. Figure 2.2 shows a 
catheter. The manufacture and materials used in these catheters are detailed in 
Appendix 2.
i i)  Testing of the catheters. The constructed catheter was tested under 
pressure by sealing the end o f part A (Figure 2.2) and then forcing saline into  
the catheter through a syringe w ith  a filed  down serum 5 needle inserted into
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Figure 2.2  Aortic catheter. M aterials used in the construction 
of the catheter are detailed in appendix 2.
the top of the catheter. I f  there was any leakage, the catheter was discarded.
The main points of d ifference from  the earlier published methods 
(Browning et al 1970) are tha t this aortic  catheter has an additional anchor 
point on part A to aid securing and it  has been bent at the neck, so tha t the 
catheter emerges from  the neck of the ra t at righ t angles to the neck.
2.2:3 Vena caval catheterisation
The vena caval catheter described here is new but was developed irr
consultation w ith  Ms. Susan G of fo rd  from  Professor Ledingham’s Department, 
The London Hospital.
Construction o f catheters. The vena caval catheter, like the aortic  
catheter, also consisted of 4 pieces of polythene, welded together by heating. 
Figure 2.3 shows a constructed catheter. The construction o f the catheter and 
the materials used in its making are detailed in Appendix 3.
2.2:4 Im plantation of aortic and IVC catheters (Figure 2.4)
Catheters were sterilised overnight in a 5% hibitane/alcohol solution. 
Before im plantation, they were soaked in sterile  saline to  remove traces of
antiseptic solution. Instruments used fo r the operative technique were sterilised 
by boiling.
Rats were anaesthetised w ith  ether. Before the operation the abdomen 
and a small area at the back of the neck were shaved and cleaned w ith  5% 
hibitane/alcohol solution. An incision was made from  pubis to  xiphisterum along 
the m idline through the skin and body wall to expose the. gut. The gut was 
re flected  to  the righ t and covered w ith  s te rile  saline soaked gauze. The aorta 
was carefu lly exposed w ith  the fingers, removing any connective tissue and fa t. 
The psoas muscle to  the le f t  o f the aorta was cleared o f fa t and connective 
tissue.
The aortic catheter was positioned approximately as shown in Figure 2.4, 
A sharpened guide needle was passed through the psoas muscle to  the
subcutaneous tissue of the back. The needle was then turned and passed
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Figure 2.3 Vena caval catheter. M aterials used in the 
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Figure 2 .4  Position of aortic and vena caval catheters
subcutaneously up the back of the ra t and brought to the surface at the back of 
the neck between the ears. The top of the catheter (neck piece) was pushed
onto the end of the guide needle. A long thread was tied to  the anchor point
at the bottom seal of the aortic catheter. The guide needle and attached 
catheter were then pulled care fu lly  through to the neck. Care was taken not to 
pull any intra-abdominal structures, e.g. ureter, into the muscles of the posterior 
abdominal wall. The needle was removed and the catheter positioned so tha t i t  
lay f la t  on the posterior body w all. I t  was anchored into the psoas muscle 
using the attached thread. The le f t lumber vein was then freed from  the body 
w all and the top of the S-bend was passed under it ,  so tha t the fina l stra ight 
portion of the catheter was lying on top o f the aorta and parallel to- i t  (Figure
2.4). A thread was attached to the anchor point on part A of the catheter and 
was then tied into the muscle. The free end of the catheter was trim m ed to 
form  a bevel of about 45 degrees at a point 5 mm above the aortic  b ifu rcation .
A 1 ml syringe attached to a 15 cm length of polythene tubing (I.D. 0.50mm;
O.D. 0.96mm) was connected to the end of the catheter by a piece of filed  
needle tubing (serum V) and the tubing and catheter f il le d  w ith  s te rile  saline. 
The catheter was now ready to be inserted.
The aorta was occluded above the level of the renal arteries. Using a 
number 20 gauge sterile  hypodermic needle, a hole was made in the aorta 3-5 
mm below the level of the renal veins. Care was taken not to pierce the 
posterior wall of the aorta. This was best achieved by previously bending the 
number 20 needle in a r ig h t angle about 5 mm from  the end of the needle w ith  
the bevelled tip  of the needle on the side away from  the hub of the needle, 
thus v ." .i l , The needle was removed and the free end o f the catheter 
inserted through the hole in to  the aorta and gently fed down the vessel. The 
aorta was released slowly and i f  any bleeding occurred through the s ite  o f 
insertion, pressure was gently maintained until a c lot had formed. In practice 
there was l i t t le  bleeding.
The bifurcation of the in fe rio r vena cava into the iliac  veins was then 
care fu lly  exposed as well as the righ t psoas muscle. The guide needle was 
passed through the righ t psoas muscle and then subcutaneously to the back of
the neck as in the aortic catheterisation procedure. A thread was tied to the
anchor point o f the IVC catheter. The catheter was then pushed onto the guide 
needle and pulled carefu lly through to the neck. A 1 ml syringe attached to  a 
15 cm length o f polythene tubing (I.D. 0.58, O.D. 0.96 mm) was connected to 
the end of the catheter by a piece of filed  needle tubing (serum V) and the
tubing fille d  w ith  sterile  saline. The tip  of the catheter was trim m ed to  5 cm
and a stra ight edge le f t  at th e -tip . The catheter was then gently pulled back
through the muscle un til the tip  was ly ing just above the b ifurcation of the IVC.
A number 20 gauge hypodermic needle was bent as previously described. A hole 
was made in the IVC at the b ifurcation and the tip  of the catheter was 
introduced into the hole. The catheter was carefu lly pulled back through the 
muscles at the back of the neck and in doing so the tip  was carefu lly passed 
down the IVC until the A-B seal was lying at the hole in the b ifurcation. 
(Postmortem studies showed tha t when 5 cm tubing was introduced into the IVC
in this way, the tip  lay between the renal veins and the righ t atrium ). The gut
was replaced and the abdominal musculature sutured. A n tib io tic  (polymyxin, 
bacitracin, neomycin dispray; Stuart Pharmaceuticals) was applied to the sutures 
and the skin was closed.
The ra t was turned over and from  the point of extériorisation o f the-
catheters, the skin was incised longitudinally until the neck anchor points on the 
catheters were exposed, usually 1.5 to 2 cm. A suture was tied round th is
anchor point and tied into the muscles of the neck, thus preventing the ra t 
from  pulling the catheters out of the aorta or the IVC. A second suture was 
tied  round the 90° bends and this too was tied into the muscle. A n tib io tic  was
applied to the wound and the skin sutured.
The end of the catheters were plugged w ith  1 cm lengths of stainless
Steel wire (0.7 mm diameter) which had been carefully rounded at one end to 
prevent damage to the catheters. Rats received ampicillin (125 mg)
subcutaneously.
The day a fte r im plantation, the catheters were fille d  w ith  0.04 m l o f 
1000 units/m l heparin.
2.2:5 Performance of aortic and IVC catheters.
A o rtic  and IVC catheters proved to be highly successful. Patency was 
maintained by daily flushing o f catheters, 0,04 ml of s te rile  saline was injected 
f irs t,  followed by 0.04 ml heparin (1000 units/m l) in the aortic catheter and 0.05 
ml of heparin (1000 units/m l) in the venous catheter.
During my f irs t year o f work there was considerable variation in the 
duration of catheter patency. However, w ith tim e most catheters remained 
patent fo r at least 3 weeks. O f the last 30 rats catheterised w ith  the
intention of prolonged infusion, 20 were satisfactory fo r infusion and recording 
fo r 2-3 weeks a fte r implantation of catheters; 7 were satisfactory fo r 1-2
weeks a fte r implantation and 3 fo r 0-1 week a fte r im plantation. Postmortem 
studies in 28 rats showed no macroscopic damage to the kidneys in marked 
contrast to the results obtained earlier w ith  carotid and jugular catheters.
A o rtic  and IVC catheters are thus clearly suitable fo r longterm infusion 
studies w ith  measurement of a rte ria l pressure.
2.3 MOBILITY OF CATHETERISED RATS IN THEIR CAGES
2.3:1 Small restraining cage.
Previous studies involving infusion of substances and measurement of 
a rte ria l pressure in rats have used small restraining cages (Riegger, Lever,
M illa r, Morton and Slack 1977). Most commonly the cages are perspex
cylinders which are adapted to  prevent movement of the ra t in any d irection. 
This method, perhaps suitable fo r short-term  studies, is c learly not suitable fo r 
prolonged infusion studies. I needed a technique where the ra t would be less 
restrained.
.2.3:2 Spring and balance system.
This part o f the technique was developed by Dr Jorge Casals-Stenzel o f 
Sobering AG in Berlin. Before starting work in Glasgow, I spent one month 
w ith  him in Berlin learning the technique.
A fte r  implantation of catheters, rats were allowed a period o f
acclim atization in metabolic cages (Techniplast Forth-Tech Services L td .
M idlothian, Scotland) (Figure 2,5). A 10.5 cm length of perspex cylinder was 
added to the top of the standard cage to raise its  height to  56.5 cm. This 
allowed the ra t to stand on its  hind legs w ithout reaching the upper rim . The 
cage was closed by a perspex lid  w ith  a 10 cm hole in its  centre.
A fte r  the period of acclim atization, rats were connected to  the spring
and balance system (Figure 2.5). This comprised a 25 cm length o f stainless
steel spring through which passed extensions of catheters connecting the ra t
w ith  blood pressure recorder and infusion pump. The spring allowed freedom o f 
movement, prevented tangling and protected the catheters, 60 cm lengths of 
polythene tubing were used fo r the a rte ria l extension (I.D, 0.58mm; O.D. 
0.96mm); 120 cm lengths of tygon tubing (I.D. 0.5mm; O.D. 1.53mm) fo r  the 
venous extensions; 2.5 cm lengths of stainless steel needle tubing joined 
catheters as shown in Figure 2.6. A 3.0 cm length o f s ilastic  tubing fixed  to 
the end of the spring and f it t in g  snugly over the connection, lay flush w ith  the 
neck and served to  protect the catheters at a potentia lly  vulnerable po in t. 
A rte ria l and venous extension catheters were f ille d  w ith  heparin (1000 un its /m l) 
and 5% dextrose, respectively. The spring was attached to  a m etal rod, pivoted 
at its  m id-point to a vertica l stand 9 cm higher than the cage top. The weight 
of the spring and attached ra t were counterbalanced by screwed weights (Figure
2.5). Thus, when the ra t stood, the spring and catheters rose. When not in use 
fo r recording, but when connected to the ra t, the a rte ria l and venous catheters, 
emerging from  the top of the spring were plugged, coiled and taped. Otherwise 
the a rte ria l catheter was connected to a pressure transducer fo r  blood pressure
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Figure 2.5 Upper part of metabolic cage with the spring and 
balance system. The metabolic details are given later in Figure 2.8  
B rief details : rat's  catheters are connected to elongated catheters, 
which are protected by the spring.
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Figure 2.6 Details of connection of rat's  catheters to 
elongated catheters.
recording and the venous catheter to a pump fo r continuous infusion. A plastic 
swivel at the top of the spring prevented tangling and tw is ting  of the spring.
2.3:3 Connection o f ra t to spring and balance system.
In in it ia l studies, rats were connected to the spring balance system under 
ligh t ether anaesthesia. The catheters were flushed as previously described and 
the extensions, fille d  w ith  heparin and 5% dextrose, were connected by needle 
tubing. The extensions were threaded through the spring un til the s ilastic  tubing 
lay flush w ith  the neck of the ra t. The ra t was then placed in the metabolic 
cage and the spring attached to the pivoted rod. In la te r studies, rats were 
conscious during connection.
2.3:4 Comparison of small cages and large cages.
Small cylindrica l cages, while suitable fo r short-term  infusions are clearly 
unsuitable fo r infusions lasting longer than 12 hours. The act of restraining may 
impose considerable stress on the animal and there may be more d iff ic u lty  in 
maintaining steady state conditions. I tested the e ffec t o f d iffe ren t cages on 
the level of a rte ria l pressure. Six rats w ith  aortic and IVC catheters were 
placed in small cylindrica l cages 5 days postoperatively and a rte ria l pressure 
measured fo r 30 mintues, A fu rthe r 6 rats were placed in large cages 5 days 
postoperatively and mean a rte ria l pressure measured fo r 30 minutes. Figure 2,7 
shows the e ffec t on pressure. The 6 rats in small cages had a mean pressure 
of 120 + 2,8 mmHg while those in the large cages had a mean pressure o f 106.6
2.6 mmHg,
2.4 MEASUREMENT OF ARTERIAL PRESSURE AND HEART RATE.
A rte ria l catheters, were connected to  Elcomatic EM 750/751 transducers 
via a length o f polythene tubing (800/100/200 Portex) and needle tubing (Star 
Everett serum V). The transducer was connected to  EM 720 pen recorder 
(Elcomatic, K irk ton fie ld  Road, Neilston, Glasgow G78 3PL) and calibrated against 
a standard mercury manometer. A damping mechanism was bu ilt into the 
recorder c ircu it to give a true mean arte ria l pressure. Heart ra te  was
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Figure 2 .7  Comparison of large and small cages. Mean a rte ria l 
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measured during recording of a rte ria l pressure by speeding up the trace  un til the 
individual pulse waves were visible and countable.
2.5 CONTINUOUS INTRAVENOUS INFUSION
Continuous intravenous infusion was given by a Dascon pump (Table 2.1) 
w ith  a variable flow  ra te . Usually I chose a rate of 2.4 mis per 24 hours. 
Details o f the reagents used fo r infusion are given in Table 2.1 
2,5:1 Angiotensin II
Asp^-Val^-angiotensin II amide was dissolved in 5% dextrose, fo r  stock 
solutions, at a concentration o f lO ug /m l. I t  was frozen in aliquots and stored 
at -20°C until used. Longterm infusions were diluted from  the stock to  a 
concentration of 2.4ug/m l, Fresh infusate was made up daily.
The potency o f stock solutions and the daily infusâtes were tested at the 
end of the experiment by bioassay in the anaesthetised ra t using freshly 
prepared standard angiotensin II, as described by Peart (1955). W ith this 
method, no solution tested showed deterioration greater than 10%. I did these 
assays myself.
2.5:2 Saralasin.
Saralasin was supplied in two forms (1) In solution and (2) in powder 
form  (Table 2.1).
Solutions were frozen at -20° and a new vial defrosted as needed. 
Saralasin in powder form  was stor&d in an a ir-tigh t, m oisture-free, container. 
The saralasin was then placed, in another container fille d  w ith  dry R ite  as 
saralasin is hydroscopic. I t  was stored at room temperature- (15-30°C) and 
protected from  ligh t. Once dissolved i t  was frozen at -20°C .
Saralasin was tested in conscious rats. F irs tly  control intravenous 
injections of angiotensin II (50 or 100 ng) were made and the pressor response 
noted. Saralasin was then infused at the ra te used in experiments fo r  2 hours 
and the angiotensin II intravenous injections repeated.
2.5:3 Renin inh ib ito r (Table 2.1)
Table 2:1 Pumps used and solutions to be infused.
Dascon Pumps. Model 300, Uden, Holland,
Angiotensin II -  Hypertensin*^ - Ciba,
Ciba Laboratories, Horsham, West Sussex, England.
Saralasin, Norwich-Eaton Pharmaceuticals,
Norwich, New York, 13815
Renin Inh ib ito r, H77 - provided by D r M. Szelke, 
U niversity of London,
Renin inh ib itor H.77, a peptide analogue of renin substrate, was stored 
at -20°C. The inh ib ito r was allowed to defrost at room temperature fo r 30 
minutes before being weighed out. A b ility  of the analogue to  inh ib it renin was 
tested in v itro  by D r Brenda Leckie using a system based on the antibody 
trapping method o f Poulson, Burton and Haber, (1975) in which plasma renin 
reacts w ith  angiotensinogen at pH 7.0 to  produce AI, I did not do these tests 
myself,
2.6 METABOLIC BALANCE TECHNIQUE
Sodium balance was measured in some o f the experiments and the 
fo llow ing techniques were used.
2.6,1 Metabolic cages.
Rats were maintained in the modified metabolic cages described earlier - 
Figure 2.8. Rats sat on a supporting grid through which the urine and faeces 
fe ll.  The la tte r  were then separated autom atically by a funnel into d iffe ren t 
containers. Drinking water was accessible from  a bottle  at the side of the 
cage, overflow being collected in a fu rth e r container. Food was accessible
from  a detachable food hopper. The cage was designed so th a t the ra t had to
crawl into the food hopper to obtain a powdered diet. However, because of
the spring and catheters, ve rtica l bars were specially f i t te d  between the cage 
wall and the food hopper to prevent rats entering the hopper and tangling the ir 
catheters.
2.6:2 Food and water.
Rats were fed on a pellet food d iet (Oxoid L td . Modified D ie t 418)
whose composition is given in Table 2.2, D ie t 41B contained Im Eq sodium per
10 grammes food. On average a ra t consumed 1.5-2.5mEq sodium per day. 
Rats drank tap water which, in Glasgow, contains less than 0.1 mEq sodium/1. 
2.6:3 D aily balance studies.
Rats were allowed to become fa m ilia r w ith  the balance procedure fo r 3
days before implantation of catheters , and then fo r a fu rth e r 3 days a fte r
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Table 2:2 Composition of pellet food d iet, 41B*
Ingredients % Composition Vit.suppl Per k ilo  diet.
Sussex ground oats. AO Ca-D-pantothenate 0.5
Wholemeal flou r 46 Vitam in B12 3 .4
White fish meal. 8 Choline Chloride 25
Dried yeast 1 Vitam in E 1.2
Dried skimmed m ilk 3 (alpha Tocopherol Acetate)
M ineral Supplement 1 Vitam in K
V itam in supplement 1 (Menadione) 0.5
Calculated nutrients. %
Crude protein
Crude fib re
O il (ether extract)
Calcium
Phosphorus
Chlorine
Sodium
Potassium
15.91
5.05
3.17
0.85
0.67
0.34
0.23
0.50
Mineral supplement (calculated elementary analysis)
%
Calcium 21.55
Chloride 18.21
Sodium 11.79
Phosphorus 3.58
Magnesium 1.19
Urea 0.93
Manganese 0.026
Copper 0.023
Iodine 0.023
Cobalt 0.006
Potassium 0.006
Vitam in supplement. pe r kilo  diet
V itam in A 3928 I.U.
V itam in D3 982 I.U.
Thiamine 0.5 mgm
R iboflavin 1.5 mgm
N ico tin ic  acid 2.5 mgm
im plantation. The balance technique was as follows: at 11.00 a.m. water
bottles were weighed to determine water intake during the previous 24 hours. 
The water overflow was also weighed but in practice overflow  was less than 1% 
of intake. The water bottle  was emptied, re fille d  w ith  fresh tap water and 
reweighed. A clean empty overflow container was weighed. The food hopper 
was removed and weighed and any spilled food swept up and weighed - this was 
never more than 0.2g from  an average daily intake of 16 grammes. The bottom  
part of the cage was removed and replaced by a clean cage. The cage was 
rinsed w ith  d istilled w ater and the washings added to  the urine specimen before 
photometry. Urine and faeces containers were removed and replaced w ith  clean 
weighed containers. The faeces were separated from  any food which had fa llen  
into the faeces container. The spilled food was weighed. The faeces were then 
homogenized in 100 ml of d istilled  water. An aliquot o f the homogenate was 
centrifuged (2000g fo r 20 minutes) and the supernatant stored,
2.6:4 E lectro lyte  determ ination.
The sodium concentration of the urine and faeces were determined w ith  
an IL  Flame Photometer, I have done all the extractions and photometry 
myself and the coe ffic ien t o f variation fo r  60 rep licate measurements o f the 
same sample of urine was 0.7%
2.6:5 Calculations.
The intake of sodium was calculated on the basis o f daily food
consumption. The sum of urinary and faecal sodium excretion were taken as
the to ta l excretions. Balance was calculated as (weight o f food x sodium
concentration) -  sodium excretion.
2.7 MEASUREMENT OF ANGIOTENSIN II BY RADIOIMMUNOASSAY.
Angiotensin II plasma levels were determined using a m odification
(Morton, Casals-Stenzel, Lever, M illa r, Riegger and Tree 1979) of a 
radioimmunoassay fo r angiotensin II in the ra t (Poweli-Jackson and MacGregor 
1976). In some experiments the individual plasma concentrations o f angiotensin
II and angiotensin III were determined separately fo llow ing chromatography 
(Semple & Morton 1976).
2.7:1 Collection of samples.
Rat a rte ria l blood (1 m l) was drawn rapidly into an ice cold syringe 
containing 0.1 ml of an aqueous solution of 0,1 M ethylenediam inetetra-acetic 
acid (disodium salt) and 0.05M o-phenanthroline and were im m ediately chilled in 
ice. This solution completely inhibits ra t plasma converting enzyme and 
angiotensinases (Powell-Oackson and MacGregor 1976) and was used w ith  a rte ria l 
blood in a ra tio  of 1:10. Blood samples were centrifuged as soon as possible, 
in practice w ith in  5 minutes, at 5°C and 2G00g fo r 20 minutes and the plasma 
stored at -20°C to await extraction.
I did not do many o f the radioimmunoassays reported here, but I know 
the principle of the technique and have assayed a few samples.
2.8 PREPARATION OF RENAL HYPERTENSIVE ANIMALS
Rats were made hypertensive by constriction o f the le f t  renal a rte ry  
w ith  a 0.007" or 0.008" s ilver clip, the righ t kidney being le f t  In s itu  (one-clip, 
two-kidney hypertension).
2.8:1 Construction o f renal a rtery clips.
Clips were constructed from  a s trip  of silver (0.38mm x 1.0mm), A 1 
cm length of silver was cut from  the s trip  and the edges file d  un til smooth. 
The piece was then bent at its m id-point around a fee le r gauge using a rte ry 
forceps to the required size, 0.007" or 0.008". One end was then bent upwards 
at an angle of 45° to  be used fo r holding during im plantation and the c lip ’s gap 
was checked once more. Clips were sterilized in h ib itane/alcohol solution 
overnight and then soaked in s te rile  saline before im plantation,
2,8:2 Clipping of renal a rtery
Rats were anaesthetised w ith  ether, the abdomen shaved and cleaned 
w ith  hibitane/alcohol solution. An incision was made from  2-3 cm above the 
pubis to the xiphisterum in the m idline through the skin and abdominal w all to
expose the gut, which was re flected to the righ t and covered w ith  saline soaked 
gauze. The le f t  renal artery was exposed and cleared of connective tissue. 
The clip  was placed on the artery. I f  the kidney blanched, the c lip  was
removed and a smaller clip  (0.007" or 0,006") applied. The gut was then
replaced and the abdominal musculature sutured. A n tib io tic  was applied 
top ica lly  and the skin was closed. Rats received am picillin  (125 mg)
subcutaneously.
2.8:3 Measurement o f systolic blood pressure.
Systolic blood pressure was measured weekly, fo llow ing application o f the 
clip , by ta il plethysmography using a W & W 8005 recorder (Wand W E lectronic 
Instruments, CH-4002 Basel, Munchenstein, Switzerland). The ra t was warmed in 
an incubator at 37°C fo r 20 mins. I t  was wrapped in a towel w ith  its  ta il 
protruding. The pressure cu ff was pushed over the ta il up to the root, fo llowed 
by the pulse detector. Figure 2.9 shows the arrangement of cu ff and detector 
and two recordings of systolic pressure.
2.9 STATISTICAL METHODS
Student's t- te s t was employed fo r the d irect comparison of means. The
non-parametric Mann-Whitney U -test was also used to  assess s ta tis tica lly  
sign ificant differences between groups.
Dose-response curves were represented by the regression line o f response 
on the logarithm  of the dose. D ifferences between the slopes o f dose-response 
curves were analysed by F-test.
Systolic Pressure mmHg (Horizontal Scale)
Inflatable 
Cuff \
Y
Microphone
Figure 2. 9 The position of the pen recorder on the horizontal scale 
is determined by cuff pressure. The pen moves across the calibrated 
paper during deflation of the cuff. A rte ria l pulsation in the vertical 
plane is recorded by the microphone. Systolic pressure is the point 
on the horizontal scale at which pulsation ceases.
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CHAPTER 3
SLOW PRESSOR EFFECT OF ANGIOTENSIN I I  IN  THE R A T .
3.1 INTRODUCTION
Angiotensin II raises blood pressure rapidly by d irect vasoconstriction 
(DeBono et al 1963) and gradually when given by constant infusion at a dose 
below the threshold of the d irect pressor e ffec t. This slow pressor action has 
been shown in dogs (Bean et al 1979; Cowley and McCaa 1976; Cowley and 
DeCIue 1976; McCubbin et al 1965), rabbits (Dickinson and Lawrence 1963; 
Dickinson and Yu, 1971) and man (Oelkers, Schoneshofer, Schultze and Bauer 
1978; Ames et al 1965) and has been implicated in the pathogenesis o f chronic 
renal hypertension (Dickinson and Lawrence 1963; Brown, Fraser, Lever, Morton, 
Robertson and Schalekamp 1977). Its mechanism is uncertain, but a nervous 
element is like ly  (Ferrario, Giidenberg, and McCubbin 1972), resetting of 
baroreceptor reflexes and increased cardiac output Also possibly contributing 
(Cowley and McCaa 1976).
Our purpose here was to examine the slow pressor e ffe c t of 
angiotensin II in the conscious ra t, to compare i t  w ith  the maximum d irec t 
pressor response and to re la te  both to concurrent plasma concentrations o f 
angiotensin II. Sodium balance was also measured since angiotensin II sometimes 
produces sodium retention (DeBono et al 1963) and the gradual rise o f pressure 
is enhanced by increased d ietary sodium (Cowley and McCaa 1976). Water 
intake was measured as w ell, as the dipsogenic e ffe c t o f angiotensin occurs at 
low dose and may be im portant physiologically (Mann, Johnson and Ganten 1980).
3.2 EXPERIMENT 1
EFFECT OF PROLONGED ANGIOTENSIN II INFUSION ON ARTERIAL
PRESSURE, SODIUM BALANCE, WATER INTAKE AND THE RESPONSE 
TO BRIEF INFUSION OF ANGIOTENSIN II.
Eight groups of rats were studied (Table 3.1).
3.2:1 Experimental design (Groups 1 and 2)
Before im plantation of catheters, a ll rats were placed in metabolic
cages fo r 3 days fo r acclim atization. A o rtic  and IVC catheters were implanted
on day 4 using methods described earlie r (Chapter 2,2:4). Rats were allowed to
recover in ordinary re t cages on day 5 (Figure 3,1). On day 6 they were
returned to the ir metabolic cages fo r acclim atization. The experiment began on
day 9 when they were connected to the spring and balance under ligh t ether
anaesthesia. 5% dextrose in water was infused at 2.4 m l/24 hours in a ll rats
from  day 9 until day 11, Rats in group 1 then received angiotensin II at 20
ng/kg/m in fo r 7 days un til day 18, when 5% dextrose was again infused un til
day 21. Rats from  group 2 received 5% dextrose throughout (Table 3.1 and
Figure 3.1).
Sodium balance. Sodium balance was measured from  the 6th to the 21st day 
as described in Chapter 2 (2:6).
Dose-response studies. Studies testing the d irect pressor e ffe c t of angiotensin II 
were carried out in rats of group 1 and 2 on days 11,17,18 (Figure 3.1). In 
each study, angiotensin II in 5% dextrose was infused at successive rates of
30,90,270 ng/kg/m in each fo r one hour. Mean a rte ria l pressure was measured
continuously fo r one hour before commencement o f the infusion and during the 
infusion. Average basal pressure was determined by measuring the pressure 
from  the trace at 5 minute intervals, the mean basal pressure was then 
calculated as the mean of 12 readings. During infusion, blood pressure was 
measured from  the trace at 5 minute intervals and the mean of the resu ltant 12 
measurements used to calculate the change of pressure at each ra te  o f Infusion.
Table  3.1 Groups o f ra ts  and e xp e rim e n ta l p ro to c o l.
Group number Protocol
Rats received dextrose fo r 3 days, then 
A ll at 20 ng/kg/m in fo r 7 days; and fin a lly  
dextrose fo r 2.5 days.
Rats received dextrose fo r 12.5 days.
Rats received b rie f dose-response infusions 
of A ll up to 810 ng/kg/m in.
Rats received 5% dextrose at 1 m l/hour 
fo r 1 hour and then sampling fo r 
estimation of plasma angiotensin II 
concentration.
10 Rats received A ll in dextrose at 20 
ng/kg/m in fo r 1 hour -  then sampling fo r 
estimation o f plasma A ll concentration.
Rats received A ll in dextrose at 270 
ng/kg/m in fo r 1 hour - then sampling fo r 
estimation of plasma A ll concentration.
Rats received A ll in 5% dextrose at 20 
ng/kg/m in fo r 7 days -  then sampling fo r 
estimation of plasma A ll concentration.
Rats received 5% dextrose fo r 7 days and 
then sampling fo r  estimation o f plasma A ll 
concentration.
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A fu rther 7 rats o f group 3 not given prolonged infusion were used in a 
separate experiment to determine the maximum pressor response to b rie f 
infusion o f angiotensin II. Catheters were implanted and rats were acclimatized 
as fo r groups 1 and 2. Angiotensin II was infused as in the dose-^response 
studies except tha t an additional infusion was given at 810 ng/kg/m in fo r  one 
hour. A rte ria l pressure was recorded and expressed as before.
3.2:2 Analysis of results.
i) Mean a rte ria l pressure (MAP) MAP was measured from  day 9 un til 
day 21. MAP was recorded fo r 40 minutes tw ice daily a t 10.00 a.m. and at 2 
p.m. D aily MAP was taken as the average, o f 80 measurements made at one 
minute intervals. The values quoted are the average o f the daily means fo r all 
rats on a particular day.
ii)  Heart rate. Heart ra te  was measured from  day 9 un til day 21, at the 
beginning and end of the two daily periods of mean a rte ria l pressure recording. 
The daily heart rate was the mean of these measurements.
ii i)  V a riab ility  o f blood pressure. V ariab ility  o f pressure was assessed as 
the standard deviation fo r the 80 measurements made in individual rats during 
recording of daily mean a rte ria l pressure and as the coe ffic ien t of variation fo r
these measurements. The values quoted (Table 3.2) are the average of
measurements in individual rats on a particu lar day.
3.2:3 Results.
i) E ffects of prolonged A ll infusion on mean a rte ria l pressure. The
effects of angiotensin II at 20 ng/kg/m in on daily mean a rte ria l pressure are 
shown in Figure 5.2 and Table 3.2. Mean a rte ria l pressure did not increase
during the f irs t hour of angiotensin 11 at 20 ng/kg/m in in rats of group 1, but
on the morning of the fo llow ing day i t  was s ign ifican tly  increased (p< 0.01, 
paired t-tes t; p< 0.05, Mann-Whitney U-test). Thereafter i t  rose progressively 
in each o f 9 rats of group 1 reaching a peak towards the 7th day.
In a la te r experiment (3,3 ) 6 rats of group 7 were infused in the same
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Figure 3. 2 Upper Panel: Mean arte ria l pressure during a 7 day 
infusion of angiotensinÏ I  20ng/kg/m in . Lines join measurements 
from the same rat. Lower Panel: Measurements and infusions in 
9 control rats receiving 5% dextrose instead of angiotensinH.
way in preparation fo r angiotensin II estimation. Blood pressure rose slowly and 
progressively in these also. Mean a rte ria l pressure the day before angiotensin II 
was 107.5+1.1 mmHg + 5EM, in the 7 subsequent days 126.7+7.0, 141.2+6.4, 
150.4+3.8, 145.8+7.4, 150.9+3.8, 156.3+3.7, 157.8+5.5 mmHg.
On returning to dextrose, a rte ria l pressure fe ll in each ra t of group 1, 
reaching control values w ith in  4 hours. The rate of fa ll was faster than the 
previous rate of rise, but slower than the rate of fa ll on stopping a b rie f 1 hour 
infusion of angiotensin II at 270 ng/kg/m in (Figure 3.3)
Mean a rte ria l pressure in contro l rats (group 2) showed l i t t le  change 
throughout the 14 day infusion (Figure 3.2). S im ilarly in a la te r experiment fo r  
estimation of plasma angiotensin II concentration (3.3), 6 rats of group 8 showed 
l it t le  change of a rte ria l pressure during 7 days infusion w ith  dextrose. Blood 
pressure on the f irs t  day was 107.3+0.7 mmHg and on the fina l day 1 0 0 .4 jfl. l 
mmHg.
ii)  V ariab ility  o f pressure. During the rise o f mean a rte ria l pressure, 
va riab ility  assessed as standard deviation, increased s ign ificantly  (p< 0.05, t- te s t) 
on the 1st, 4th, 5th and 6th days of angiotensin infusion (days 12, 15,16 and 17 
of the experiment) compared w ith  dextrose infused controls. I t  decreased on 
re turn to dextrose infusion. However, the increase of va riab ility  assessed by 
coe ffic ien t o f variation did not reach significance though on every occasion the 
coe ffic ien t of variation was higher in experimental animals than in controls 
(Table 3.2).
i i i)  Dose-response studies. Dose-response studies were done on the day
before prolonged angiotensin II infusion began, on the 6th day of prolonged A ll 
infusion and 4 hours a fte r stopping prolonged angiotensin II infusion,  ^ A rte ria l 
pressure rose acutely during each dose-response study in each ra t end the rise 
of pressure was related to the ra te  o f infusion (Figure 3.4). Prolonged infusion 
shifted the curve upward. Thus a given rate of angiotensin infusion during 
prolonged infusion maintained a higher pressure than during the contro l period.
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Figure 3. 3 F a ll in mean arte ria l pressure on stopping 
infusion of angiotensin XI for 7 days at 20ng /kg / min. 
Comparison with the fa ll of pressure on stopping infusion 
at 270ng/kg/m in for 1 hour. Results are expressed as 
change from in itia l blood pressure before angiotensin 
infusion began. Bars indicate IS E M
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Figure 3 .4  Upper Panel: 3 Dose-Response studies in rats of 
group 1 done before, during and after prolonged A l l  infusion 
(Days 11,17 and 18 respectively) Lower Panel : 3 Dose-Response 
studies in rats of group 2 as above. Rats of group 3 received an 
additional infusion at B lO ng/kg/m in.
This occurred because a rte ria l pressure at the beginning of the dose-response 
study was higher, not because the response (change of blood pressure fo r a given 
ra te of infusion) was enhanced. Indeed the response was sligh tly  diminished. 
The slope of the curve was not s ign ificantly  d iffe ren t compared w ith  dose- 
response 1 (F-test, F=0,294). On reverting to dextrose on day 18 fo llow ing 7 
days of low dose angiotensin II, blood pressure fe ll and fo r the th ird  study, 4
hours a fte r reverting to dextrose infusion the starting level of blood pressure
was normal. On this occasion, at each rate of angiotensin infusion, there was 
now a s ign ificantly  enhanced response (F-5.958, p< 0,05).
Dose-response studies in control rats showed l i t t le  change during the 
experiment.
A separate experiment was done in a th ird  group of rats (group 3) to 
establish the maximum d irect pressor response to angiotensin. Angiotensin II 
was infused in 7 rats, as before, at the same three rates (30, 90, and 270 
ng/kg/m in) and at an additional rate of 810 ng/kg/m in. The additional increase 
of pressure at the higher dose was only 3.7 mmHg (Figure 3.4). Thus, the rise 
of pressure at 270 and 810 ng/kg/m in is probably close to  the maximum acute 
pressor e ffe c t of angiotensin II. In terestingly, the rise of blood pressure
produced by the 7 day infusion of angiotensin II at 20 ng/kg/m in was 6.6 mmHg
greater than tha t previously produced by one hour infusion a t 270 ng/kg/m in in 
the same rats, although the difference was not s ta tis tica lly  s ign ificant,
Iv) Heart ra te  Heart ra te tended to  decrease during the experiment in
both control (group 2) and experimental (group 1) animals (Figure 3.5 end Table 
3.3). The decrease was greater in the experimental group 1, but on no day 
during the experiment was heart rate s ign ificantly  lower in experimental animals 
than in controls.
v) Food and w ater intake and sodium balance. Food and water intake
were not s ign ificantly  a ffected by prolonged infusion of angiotensin II (Figure 
3.6). Sodium balance data were assessed in three ways. F irs t, comparison
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Table 3.3 H eart ra te  during prolonged ATI infusion.
Day HR - Group 1 HR - Group 2
Mean + SEM Mean + SEM
9 419.0 + 21.4 461.9 + 21.8
10 383.8 + 13.5 405.0 ■± 12.1
11 394.6 + 13.6 391.6 14.5
12 353.1 + 16.1 393.6 + 13.8
13 359.1 + 16.5 374.3 + 13.5
14 353.8 + 11,9 373.0 13.2
15 347.9 + 13.2 381.9 ± 8.3
16 342.9 ± 17.5 377.2 + 9.7
17 331.7 + 17.8 382.8 + 17.9
18 372.5 + 15.8 390.0 + 18.4
19 393.7 + 11.8 402.3 + 17.9
20 393.8 ± 20.4 390.0 + 29.8
21 358.0 i 16.5 393,0 4" 6 .5
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was made o f experimental and control groups. The only s ign ificant difference 
to emerge was during the last day of control of infusion (11th day of 
experiment) when both groups were receiving dextrose (Figure 3.7). On this day, 
control rats had a s ign ificantly  negative balance compared w ith  the experimental 
group (t-tes t, p< 0,01), The difference was mainly a ttribu tab le  to  one control 
ra t, which remained in negative balance consistently, on day 11 contributing a 
larger than usual d e fic it. A second comparison was of cumulative sodium 
balance during the 7 day infusion in the two groups. Again no sign ificant 
d ifference was apparent (t-tes t p> 0,4). F inally, cumulative balance during the 
6 days before infusion was subtracted from  cumulative balance during the 7 day 
infusion and this d ifference was compared in control and experimental groups. 
Again the difference was insignificant (t-tes t, p> 0.8) (Table 3.4)
On stopping angiotensin infusion sodium balance became s ign ificantly  
positive in the experimental group (paired t-tests, p< 0.01 fo r comparison w ith  
the fina l day of angiotensin infusion). I t  was during th is tim e tha t blood
pressure fe ll.
3.3 EXPERIMENT 2.
PLASMA ANGIOTENSIN II LEVELS DURING ANGIOTENSIN INFUSION.
My object here was to' demonstrate whether the plasma concentration 
of angiotensin II during the slow response was w ith in  or well above the
physiological range.
3.3.1 Experimental design (Table 3.1)
Plasma angiotensin II concentration was measured in 5 groups of rats: 
group 4 received 5% dextrose at 1 m l/hour fo r 1 hour; group 5 received
angiotensin II in 5% dextrose at 20 ng/kg/m in fo r 1 hour; group 6 received 
angiotensin II at 270 ng/kg/m in fo r 1 hour; group 7 received angiotensin II in 
5% dextrose at 20 ng/kg/m in fo r 7 days and group 8 received only 5% dextrose 
fo r 7 days.
Rats from  groups 4, 5 and 6 were implanted w ith  carotid type 1
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Figure 3.7 Sodium balance during prolonged dextrose and 
angiotensin infusions.
Tab le  3.4 Sodium balance.
Group 1 Group 2.
Day n mean + S.E. n mean + S.E.
6 9 0.26 +0.09 8 0.45 + 0.08
7 9 0.38 + 0.09 8 0.45 +^ 0.17 acclim atization.
8 9 0.18 + 0.13 8 0.09 + 0.16
9 9 0.27 + 0.15 8 -0 .10  + 0.12
10 9 0.15 + 0.24 8 0.01 + 0.26 dextrose infusion.
11 9 0.21 + 0.10 8 -0 .38  + 0.16
12 9 0.30 + 0.13 8 -0 .07  + 0.16
13 9 0.18 + 0.25 8 +0.05 + 0.14
14 9 0.08 + 0.13 8 +0.10 + 0.19
15 9 0.16 + 0.17 8 -0 .13  + 0.16 A ll 20 ng/kg/m in
16 9 -0 .12  + 0.23 8 -0 .06  + 0.11 or dextrose.
17 8 -0 .18  + 0.26 8 -0 .33  + 0.19
IB 8 -0 .30  + 0.22 8 — 0•18 + 0.21
19 8 +0.35 + 0.16 7 -0 .12  + 0.26
20 7 +0.50 + 0.13 5 +0.37 + 0.17 dextrose infusion
21 4 +0.30 + 0.19 2 -0 .19  + 0.16
Days 12-18; Mean cumulative balance 0.36 + 0.76 Group 1
-0 .62  + 0,62 Group 2,
catheters and jugular vein catheters (2.2:1). The follow ing day they were 
placed in small restraining cages (2.3:1) fo r infusion. A o rtic  and I VC catheters 
were implanted in rats from  groups 7 and 8, Six days a fte r the operation, they 
were connected to the spring and balance system and the infusion was begun. 
Mean a rte ria l pressure was measured daily fo r 20 minutes in rats from  groups 7 
and 8.
A t the end o f each infusion, 1.0 ml of arte ria l blood was w ithdrawn fo r 
angiotensin II determ ination (2.7), Eleven of these samples were subjected to 
chromatography, separating angiotensin II and angiotensin III which were
measured by radioimmunoassay.
3.3:2 Results
i) E ffects of prolonged A ll, prolonged dextrose and b rie f A ll
infusion on mean a rte ria l pressure. Mean a rte ria l presure rose
slowly and progressively in 6 rats of group 7, (Table 3.5) as has been described, 
in the same way as rats of group 1 in the f irs t  experiment. Six rats of group 
8 showed l i t t le  change of a rte ria l pressure during 7 days infusion w ith  dextrose 
(Table 3.5). Mean a rte ria l pressure rose rapidly in 6 rats from  group 6.
ii) Plasma angiotensin II levels. Figure 3.8 shows the plasma
angiotensin II levels fo r the d iffe ren t groups. Animals receiving control
dextrose infusions fo r 7 days (Group 8) had lower plasma angiotensin II
concentration than animals receiving contro l infusions fo r 1 hour (t-tes t, p< 0.01; 
p< 0.01, Mann Whitney) (group 4). This may be due to  the fa c t that the rats 
in group 4 were placed in small restraining cages which cause considerable 
stress. The rats were also used the day a fte r im plantation of catheters and 
only had a short 30 minute period of acclim atization. A ll these factors would 
tend to raise the plasma angiotensin II levels and therefore may explain the
difference between the two groups. In rats infused fo r 1 hour, angiotensin II at 
20 ng/kg/m in (group 5) produced a 2-fo ld increase of plasma angiotensin II 
concentration compared w ith  controls infused w ith  dextrose fo r 1 hour (t-tes t.
Table  3.5 Mean a r te r ia l pressure during  pro longed ang io tens in  I I
in fu s io n  and pro longed dextrose  in fu s io n  (Groups 7 and 8) 
and b r ie f  ang io tensin  I I  in fus ion  (G roup 6)
MAP + SEM mmHg.
Control
Day 1
2
3
4
5
6 
7
107.5 + 1 . 1
126.7 + 7.0
141.2 + 6.4 
150.4 + 3.8
145.8 + 7 .4
150.9 + 3.8
156.3 + 3.7 
157.8 + 5.5
Group 7 n = 6. Prolonged A ll 
infusion at 20 ng/kg min fo r 
7 days.
Control
Day 1
2
3
4
5
6 
7
107.3 + 0.7
104.9 + 3.4
101.6 + 1.3
101.6 + 2.7
104.9 + 1.9
108.6 + 2 .4
103.6 + 2.0
100.4 + 1.1
Group 8 n = 6. Prolonged dextrose 
infusion fo r 7 days.
Control 
1 hour la ter
101.0 + 3.5 
146.3 + 3.0
Group 6 n = 6 A ll infused at 
270 ng/kg/m in fo r 1 hour.
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Figure 3. 8 Plasma angiotensinII levels in 5 groups 
of rats.
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p> 0.1; p< 0,05, Mann Whitney U test). Infusion at 270 ng/kg/m in fo r 1 hour 
produced a 32-fold increase (t-tes t, p< 0.01; p< 0.001 Mann Whitney U Test). 
In rats infused fo r 7 days, angiotensin II at 20 ng/kg/m in produced a higher 
concentration of peptide than did control infusions fo r 7 days (t-tes t, p< 0.01; 
p< 0,001, Mann Whitney U test). Animals infused w ith  angiotensin II at 20 
ng/kg/m in fo r 7 days had a higher concentration of peptide than animals infused 
w ith  A ll fo r 1 hour at 20 ng/kg/m in, although the difference was not s ignificant. 
Thus, infusion of angiotensin II a t 20 ng/kg/m in, a dose which over 7 
days produced a large rise of pressure, produced only a small rise of plasma 
angiotensin II levels. Indeed levels in some rats were w ith in the range found in 
dextrose-infused controls. As expected, b rie f infusion of A ll at 270 ng/kg/m in 
produced a much greater plasma concentration of peptide, but a s im ilar rise of 
pressure.
Table 3.6 shows the plasma angiotensin II and angiotensin III levels from  
the 11 samples subjected to chromatography to separate angiotensin II and 
angiotensin III. The results confirm  earlier reports (Sample and Morton 1976) 
tha t measurement of angiotensin II in ra t plasma w ithout chromatography 
overestimates the concentration of peptide measured as angiotensin II. Some of 
the excess can be accounted fo r by angiotensin III which is present in ra t blood 
in re la tive ly  high concentrations and which reacts w ith the antiserum used in 
this assay.
I t  was interesting tha t infusion of angiotensin II decreased rather than 
increased the proportion of angiotensin III, During infusion of angiotensin II a 
higher proportion of the immunoreactive m ateria l chromatographed w ith  
angiotensin II, a lower proportion w ith  angiotensin III. Thus, levels of 
c ircu la ting peptides measured as angiotensin II were not falsely elevated by an 
increased proportion o f angiotensin III,
3.4 COMMENT.
In a general discussion at the end of this thesis I shall consider the
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mechanism of the slow-pressor e ffec t and its possible relevance in renal 
hypertension. This in terim  discussion is concerned here w ith  points raised by 
experiments 1 and 2,
The slow response has been noted previously in rabbits (Dickinson and 
Lawrence 1963); dogs (McCubbin et al 1965, Cowley and DeClue 1976, Cowley 
and McCaa 1976, Bean et al 1979) and man (Oelkers et al 1978) but in none of 
these did i t  develop as markedly or as rapidly as in the ra t. Its magnitude in 
the ra t a fte r 7 days was s im ila r to  the maximum direct response. Also the 
slow response developed at a plasma concentration of angiotensin II w ith in  or 
close to the physiological range. This implies tha t a small but sustained 
increase in the plasma concentration of endogenous angiotensin II could have a 
marked e ffe c t on blood pressure.
The rate o f change o f pressure on stopping infusion of angiotensin II 
was d iffe ren t fo r fast and slow responses. A rte ria l pressure fe ll to  control 
values- w ith in  2 minutes of stopping b rie f pressor infusions of angiotensin II, but 
took 4 hours to reach contro l on stopping 7 day infusions at lower dose. The 
duration of angiotensin infusion is known to determine the subsequent rate of 
fa ll of pressure in rabbits (Dickinson and Yu, 1967b).
Dose-response studies testing the d irect pressor response of angiotensin 
II during the slow rise of pressure showed an upward sh ift in the curve re la ting  
a rte ria l pressure and rate o f angiotensin infusion, a given ra te maintaining a 
higher pressure. Bean et a l (1979) showed this in the dog, demonstrating an 
upward sh ift in the curve re la tin g  a rte ria l pressure and plasma angiotensin II
concentration.
The th ird  dose response study was begun 4 hours a fte r stopping
infusion of angiotensin II, at a time when arteria l pressure was normal. The 
pressor response to angiotensin II during this study was enhanced, Skulan,
Brousseau and Leonard (1974) made a sim ilar observation in renal hypertensive
rats. Two days a fte r unclipping, when blood pressure had fa llen to normal, the
pressor response to angiotensin II was increased. Ten Berg and de Jong (1980) 
suggested tha t the enhanced response was a result o f altered rea c tiv ity  o f the 
cardiovascular system. One explanation fo r the altered response and fo r the 
rise of pressure is tha t s tructura l changes occur in resistance vessels during (and 
possibly because of) the rise of a rte ria l pressure and that these persist fo r a 
tim e when blood pressure fa lls . Folkow (1971) has discussed the importance o f 
this mechanism and the way in which i t  can a lte r the response to 
vasoconstrictor agents.
Another explanation fo r the enhanced response derives from  the theory 
of prior occupancy by endogenously generated angiotensin II (Marks, Thurston, 
Bing, and Swales 1979). During infusion of angiotensin II, endogenous renin and 
angiotensin II would be suppressed. On stopping the infusion there w ill be a 
period when endogenous angiotensin II is low because renin release is s til l 
suppressed and exogenously infused angiotensin II is no longer present in blood. 
Under these circumstances a high proportion of receptors w ill be unoccupied and 
the response to infused angiotensin II correspondingly larger.
Angiotensin II alters the urinary excretion o f sodium and water (Brown 
and Peart 1962); stimulates drinking (Epstein et al 1970) and as a result of th is 
la tte r action suppresses feeding (McFarland and Rolls 1972), but it  is not certa in 
whether these are physiological effects o f the blood-borne peptide. Water and 
food intake and urinary sodium excretion did not change in our experiment 
during an infusion of angiotensin II which did raise blood pressure. Thus, 
thresholds of the urinary, dipsogenic and feeding effects of angiotensin II are 
like ly  to be higher than the threshold of the slow pressor e ffec t. Mann et al 
(1980) consider the threshold fo r the dipsogenic e ffec t in rats to  be a t or above 
200 pg of angiotensin Il/m l of plasma. In our experiment infusion of angiotensin 
II at 20 ng/kg/m in fo r 7 days raised plasma angiotensin II concentration to 214 
pg/m l, at which we fa iled  to demonstrate an e ffec t on drinking. However, the 
two studies are not necessarily incompatible as clear-cut e ffects on drinking
6 6 .
only occurred at higher plasma concentrations of angiotensin in the experiment 
o f Mann et al (1980).
Separate measurements were made of plasma angiotensin II and
angiotensin III as i t  was possible tha t angiotensin III m ight be formed from
angiotensin II during infusion fa lsely elevating the estimate of angiotensin Il- lik e
m ateria l. In fa c t the opposite occurred, the plasma concentration of angiotensin 
II increased while tha t of angiotensin III decreased (Table 3.6). A possible 
explanation fo r this suggested by the recent demonstration (Garcia del Rio,
Smellie and Morton 1981) tha t the nonapeptide, des-asp^ Ile^ angiotensin I, is
present in ra t blood and is converted d irec tly  in vivo to angiotensin III and does
not form  angiotensin II. I f  this nonapeptide is its e lf produced d ire c tly  or 
ind irec tly  by renin and if ,  as is like ly , infusion of angiotensin II inhibits renin 
release, the nonapeptide and thence angiotensin III w ill decrease during infusion 
of angiotensin II.
Our experiment tests a role fo r angiotensin II as a blood-borne
hormone. I t  has not tested roles which are thought to exist fo r angiotensin II 
generated loca lly in brain or blood vessels. Such actions cannot be 
quantita tive ly assessed by intravenous infusion of peptide.
3.4:1. Experiments 1 and 2: conclusions and fu ture  experiments.
Our main conclusions are tha t the slow pressor e ffe c t of angiotensin II 
develops at a plasma concentration o f the peptide which is close to, or w ith in , 
the physiological range and which has l i t t le  or no e ffe c t on food or water
intake or on urinary excretion of sodium and tha t the magnitude o f the slow
e ffe c t a t 7 days is s im ilar to the maximum direct pressor response produced by
larger doses of angiotensin II. Experiments 1 and 2 have been w ritte n  up and 
published in the American Journal of Physiology (Brown, Casals-Stenzel, Gofford, 
Lever and Morton, 1981). I t  has suggested a number o f fu rthe r experiments.
F irs t, I would like  to study the mechanism of the slow e ffe c t. There
are several possibilities here (Brown, Fraser, Lever at al 1977, Dickinson and Yu
D /  ,
1971), An action of angiotensin II on the nervous system seems like ly  (Ferrario 
et al 1972), but there are many levels of the peripheral and central nervous 
system at which angiotensin II could act. I shall pursue this idea fu rthe r in the 
ra t, I plan to measure plasma noradrenaline and adrenaline during the slow rise 
of pressure to indicate whether there is overactiv ity  of the sympathetic nervous 
system and then, by use o f pharmacological agents such as bethanidine, an 
adrenergic neurone blocking agent or reserpine which depletes adrenergic 
neurones, to block the action of the sympathetic nervous system, before and 
during a prolonged infusion of low dose angiotensin II.
My second plan is to determine whether infusion of angiotensin II at 
low dose, fo r longer than one week produces a fu rthe r increase in a rte ria l 
pressure, possibly to the point where complications or malignant phase 
hypertension develop. With Ms. Sheila C lark I propose to infuse angiotensin at 
20 ng/kg/m in fo r 14 days. Experiments have begun, but so fa r only one ra t has 
been completed. Figure 3.9 illustrates the rise of pressure over the 14 day 
period and compares i t  w ith  the mean rise of pressure in the 9 rats o f group 1 
which received angiotensin II fo r one week only. Mean a rte ria l pressure 
continued to rise a fte r 7 days of angiotensin II infusion reaching a peak level of 
176,2 mmHg at the end of the 14 day infusion. The fact, tha t pressure 
continued to rise during this constant infusion suggests that the slow pressor 
e ffe c t of angiotensin II may have an im portant role to  play in a rte ria l pressure 
regulation and in the maintenance of some hypertensive states, although my 
experiments do not establish such a role.
There is also a need to assess the contribution of the slow e ffe c t to  
the maintenance of renal hypertension and the next chapter deals w ith  some 
aspects o f this interesting but unanswered question.
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CHAPTER 4
PROLONGED INFUSIO N OF SARALASIN IN  NORM AL AND
HYPERTENSIVE RATS.
4.1 INTRODUCTION.
. With the synthesis of angiotensin II analogues, such as saralasin, tools 
were provided w ith  which to study the role of angiotensin II in control o f 
a rte ria l pressure in normotensive and hypertensive states. Use o f these and 
other antagonists o f the renin-angiotensin system in the acute phase of renal 
hypertension have established fa ir ly  w ell tha t the rise of pressure at this stage 
is partly or wholly a result of the d irect vasoconstrictor e ffe c t of angiotensin II 
(Pals, Masucci, Denning, Sipos and Fessier 1971b; Coleman and Guyton 1975; 
Thurston and Swales 1974; Freeman, Davis, Watkins and Lohmeier 1977; 
Masaki, Ferrario, Bumpus, Bravo and Khosla 1977), Dose-response studies also 
support the idea (Caravaggi, Blanchi, Brown, Lever, M orton, Powell-Jackson, 
Robertson and Semple 1976).
Chronic renal hypertension is less easy to explain. Blood pressure may 
be higher but plasma levels o f renin and angiotensin II are not now high enough 
to raise blood pressure by acute vasoconstriction alone (Blanchi, Baldoli, Lucca 
and Barbin 1972; Brown, Cuesta, Davies, Lever, Morton, Padfield, Robertson, 
Trust, Blanchi and Schalekamp 1976). A ttention  therefore turned to additional 
mechanisms. One possibility was the slow pressor e ffe c t of angiotensin II. 
Prolonged infusion o f -saralasin fo r 12 hours into renal hypertensive rats was 
used to test this second hypothesis (Rlegger et al 1977; Bing, Russell, Swales 
and Thurston, 1981). One group (Riegger et al 1977) found a gradual decrease 
of pressure to normotensive levels w ith  saralasin; the other (Bing e t al 1981) 
found no decrease. My th ird  experiment had its origin in this disagreement. I 
fe lt  i t  was im portant to resolve the m atter before the role of a slow pressor 
e ffe c t of angiotensin II in renal hypertension could be properly assessed.
There were several differences between the experiments. A t the tim e, 
none seemed particular y im portant, but the difference on which I decided to 
concentrate f irs t was tha t one group (Riegger et al 1977) infused saralasin by 
day, the other group (Bing et al 198,1) infused i t  by night, A possibility I 
considered was that saralasin produced a diurnal e ffe c t on a rte ria l pressure, 
raising i t  by night, reducing i t  by day. I f  this diurnal e ffe c t was greater in 
hypertensive than in control animals, the difference would be explained.
My object, therefore, was to Infuse saralasin fo r long enough to  test this 
idea in normal and renal hypertensive rats. So fa r only 3 m ild ly  hypertensive 
and one severely hypertensive rats have been infused and so I have not yet 
properly assessed the role of angiotensin in renal hypertension, but the results in 
normal rats were interesting and unexpected. The study of normal rats has 
been completed and a prelim inary communication has been given (Brown and 
Lever, 1981). The findings are described below in experiment 3.
4.2 EXPERIMENT 3
EFFECT OF PROLONGED SARALASIN INFUSION ON ARTERIAL PRESSURE 
AND SODIUM BALANCE IN NORMAL RATS.
4.2:1 Experimental design.
Eight rats were studied. Figure 4.1 shows the protocol. A o rtic  and IVC
catheters were implanted as previously described (2.2:4). A fte r  the usual period
of recovery and acclim atization, rats were connected on day 6 to the spring and
balance system. The experiment began on day 7 when 5% dextrose was infused
fo r 2 days as control, then saralasin was infused at 10 vtg/kg/min fo r 4 days,
and fin a lly  dextrose fo r the last 2 days (Figure 4,1), Saralasin infusions were
begun at 9.00 a.m. in 6 rats and at 9.00 p.m. in 2 rats.
Sodium balance was measured from  the 7th day, as described in Chapter
2 (2:6). Mean a rte ria l pressure (MAP) was recorded continuously from  day 7
until the end of the experiment 8 days la te r. Traces were analysed as fo llows:
2-hourly mean values. A single value of MAP was obtained from  the
Dextrose Saralasin lOjüt g /k g /m in Dextrose
Recovery
Implantation
of
catheters
Connection to spring
Acclimatisation
to
metabolic cage
I--------------r - --------------- 1---------------- 1------------
0 2 4 6
Days
Figure 4 .1  Experimental protocol
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trace every 30 minutes. Each 24 hour period was then divided into twelve 2 
hourly intervals i.e. 0.30-2.00; 2.30-4.00 a.m. etc. and the average of four 30 
m inute measurements during each 2 hour in terval was calculated to give a 2 
hour value fo r blood pressure fo r individual rats.
M inute to minute va riab ility  o f pressure. More frequent readings were used
to  assess va riab ility  of a rte ria l pressure. Th irty  measurements of a rte ria l
pressure made at 2 minute intervals between 9.00 a.m. and 10.00 a.m. each day 
were used in every ra t to calculate va riab ility  which was expressed as before 
(Chapter 3.2:2) as the standard deviation and coeffic ien t o f variation fo r the 30 
measurements.
4.2:2 Results.
Prolonged infusion of saralasin produced four main changes: a rapid
pressor response, a gradual rise of pressure as w ith angiotensin II in low dose 
(Chapter 3), increased diurnal variation of pressure and increased va riab ility  of 
pressure assessed minute to minute.
1) Rapid pressor response. Infusion of saralasin at 10
Ug/kg/min raised a rte ria l pressure acutely in a ll rats from  a mean level o f 
105.8 + 3.0 mmHg before infusion to 126.8 + 6.3 mmHg w ith in  5 minutes 
(p< 0.01, paired t-tes t). Pressure then fe ll w ith in 15 minutes to pre-infusion 
levels despite continuous infusion o f the saralasin,
2) Gradual increase of blood pressure A fte r this transitional
increase in pressure and in the 6 rats which started saralasin infusion at 9.00 
a.m., mean a rte ria l pressure remained at control levels fo r 12 hours un til 
approximately 10.00 p.m. when pressure began to  rise. Thereafter i t  rose 
progressively, but w ith  increased diurnal variation (described la te r) to  reach a 
peak 21 mmHg higher than control on the 4th day (Figure 4.2). Mean a rte ria l 
pressure fo r the group was 109 + 0.4 mmHg the day before saralasin, 131 + 0.6 
mmHg on the 4th day o f infusion (n = 6, paired t-te s t, p< 0,001). In the 2 rats 
starting  saralasin infusion a t 9.00 p.m. MAP also rose progressively. MAP fo r
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these was 100.3 + 0.5 mmHg the day before saralasin infusion, 124.9 + 0.9
mmHg on the 4th day of infusion.
On returning to dextrose, mean a rte ria l pressure fe ll in each ra t 
reaching control values w ith in  6 hours. In the rats stopping saralasin at night, 
mean a rte ria l pressure fe ll in these rats also reaching control values w ith in  4 
hours.
3) Diurnal changes of a rte ria l pressure Mean a rte ria l pressure varied
during both the contro l and experimental periods, tending to  Increase during the 
night between 9.00 p.m. and 9.00 a.m. and to decrease during the day between
9.00 a.m. and 9.00 p.m. (Table 4.1). This normal diurnal variation increased 
during saralasin. The rise in mean a rte ria l pressure during the night in the
experimental period was s ign ificantly  greater than the rise occurring in the same 
rats in the control period (p< 0.05, paired t-tes t), but on the 1st and 2nd days 
of saralasin only. The decrease in pressure during the day, however, was not 
s ign ificantly  greater in the experimental period compared to tha t during the 
control period. The rises and fa lls  of pressure were in themselves significant 
both during the control and experimental period (p< 0.05, paired t-tes t) (Table 
4,1). Interestingly, in the rats starting  saralasin at 9.00 a.m., mean a rte ria l 
pressure remained at control levels until approximately 10.00 p.m. when i t  began 
to rise. Mean a rte ria l pressure in these animals at 10.00 a.m. was not
s ign ificantly  d iffe ren t from  mean a rte ria l pressure at 10.00 p.m. (p< 0.4, paired 
t-tes t). Saralasin had thus prevented the usual decrease in pressure during the 
day.
The increase in diurnal rhythm o f pressure was also apparent in the 2 
rats which started saralasin infusion at night (Figure 4.2).
4) Minute to minute va ria b ility  of pressure. Table 4.2 shows
va riab ility  of mean a rte ria l pressure assessed by standard deviation and 
coe ffic ien t of variation, before, during and a fte r saralasin. Saralasin increased 
va riab ility  assessed by standard deviation on the 1st, 3rd and 4th days of its
Table 4.1 D iurnal changes of mean a rte r ia l pressure
during saralasin.
Day MAP mmHg. MAP
7 9 p.m. 103.7
8 9 a.m. 112.4
9 p.m. 104.7
9 9 a.m. 111.2
* * * * * * * * * * * * * *
9 p.m. 112.1
10 9 a.m. 130.7
9 p.m. 118.3
11 9 a.m. 133.5
9 p.m. 117.1
12 9 a.m. 130.6
9 p.m. 123.9
13 9 a.m. 132.2
* * * * * * * * * * * * * *
9 p.m. 111.1
14 9 a.m. 116,5
9 p.m. 107.1
15 9 a.m. 115.2
*  p< 0.05 
n = 6
+8.7
-7 .7
+6.5
+18.6*
-12 .4
+15.2*
-16 .4
+13.5
- 6.7
+ 8.3
5.4
9 .4  
8.1
Table 4.2 Standard deviation and coeffic ien t of variation  
during prolonged saralasin infusion, (n = 8).
Day n Standard deviation C oeffic ien t of variation
Dextrose
8 B
9 8
4.24 + 0.40
4.84 + 0.58
3.93 + 0.34 
4.48 + 0.5
Saralasin
10
11
12
13
6.53 + 0.84* 
5.80 + 1.06
6.18 + 0 .60* 
6.63 + 0 .68**
5.15 + 0.61 
4.39 + 0.77
4.75 + 0.53 
4.92 + 0.47*
Dextrose
14
15
5.64 + 1.02 
6.33 + 0.86
5.07 + 0.89 
5.69 + 1.07
*p< 0.05 significance when compared w ith  day 8.
**p<  0.01 Less frequent but s t il l s ignificant changes were 
found when compared w ith  day 9.
/ 4
infusion and by coe ffic ien t of variation on the 4th day only. Neither change 
was marked or highly significant.
5) Food and water intake and sodium balance (Figure 4.3) Food and water
intake were not s ign ificantly  affected by prolonged infusion of saralasin. Urine 
volume, however, was s ign ificantly  greater on the 2nd day of saralasin infusion 
compared to  the 1st and 2nd days o f dextrose (p< 0.05, paired t-tes t). Sodium 
balance was not s ign ificantly  affected.
4.3 COMMENT
Saralasin infused into normal rats had in it ia lly  a b rie f pressor response 
observed in the f irs t  few  minutes o f infusion. This response is well known and 
is probably partly  mediated by angiotensin-like agonist action on vascular 
receptors (Pals et al 1971a) and also by an action on the central or peripheral 
autonomic nervous system (McGrath et al 1977).
A fte r this acute response, saralasin had a second slow developing pressor 
action, sim ilar in many ways to that seen previously w ith  angiotensin II (Figure
3). The inh ib itor raised mean a rte ria l pressure gradually by 22 mmHg in 4 days. 
A rte ria l pressure in s im ilar rats receiving angiotensin II at 20 ng/kg/m in 
increased by 40.7 mmHg in 4 days (Chapter 3).
Saralasin also increased the diurnal variation o f pressure, I did not know 
at the tim e i f  increased diurnal changes o f pressure also occurred in the rats 
receiving angiotensin II because a rte ria l pressure had not been recorded 
continuously in my earlier experiment (Chapter 3). I decided to infuse
angiotensin II in a fu rthe r group o f rats w ith  continuous measurement o f a rte ria l 
pressure,
4.4 EXPERIMENT 4
EFFECT OF PROLONGED ANGIOTENSIN II INFUSION ON DIURNAL 
CHANGES OF ARTERIAL PRESSURE.
4.4:1 Experimental design.
Six rats were studied. Figure 4.4 shows the protocol. Rats were
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Figure 4 .4  Experim ental protocol
prepared as fo r experiment 4, in which saralasin was infused, and followed an 
identica l protocol except that angiotensin II was infused at 20 ng/kg/m in fo r 4 
days instead of saralasin (4.2:1). Infusions were begun at 9.00 a.m. in all 
animals. Sodium balance was not measured as this had been done previously 
(Chapter 3) w ith  negative results (Figure 3.7). MAP was recorded continuously 
from  day 7 until the end of the experiment 8 days la te r. Traces were analysed 
as before (4.2:1)
4.4:2 Results
Prolonged infusion o f angiotensin II produced sim ilar changes to saralasin: 
a gradual rise of pressure and increased diurnal variation of pressure.
Infusion of angiotensin II at 20 ng/kg/m in raised a rte ria l pressure acutely 
in a ll rats, blood pressure increasing from  a mean level of 109.1 + 2.0 mmHg 
before infusion to 122.2 + 3.3 mmHg w ith in  10 minutes o f starting the infusion 
(p< 0.01, paired t-tes t). Thereafter pressure rose progressively to reach a peak 
41.7 mmHg higher on the 4th day o f infusion (Figure 4.5) (n = 6, paired t-te s t, 
p< 0.001). On returning to dextrose, mean arteria l pressure fe ll in each ra t 
reaching control levels w ith in  4 hours. Angiotensin II also increased the diurnal 
changes of pressure (Table 4.3). The rise in pressure during nights o f 
angiotensin infusion were s ign ificantly  greater than the change occurring in the 
same rats during the night in the control period (p< 0.05, paired t-tes t). The 
fa ll o f pressure during the day was also greater than tha t during the day in the 
control period, but was s ign ificantly  greater only on the 3rd day of angiotensin 
(p< 0.05, paired t-tes t).
4.5 COMMENT.
Angiotensin II infused into normal rats had an acute pressor e ffe c t 
observed in the f irs t few minutes of infusion. Infused at this ra te  in my earlier 
experiment (Chapter 3) it  had no in it ia l pressor e ffec t. We cannot explain this 
d ifference, but we do know from  earlier experiments that this particu lar ra te of 
infusion is near the threshold fo r the d irect vasoconstrictor e ffec t of angiotensin
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Table 4.3 D iurnal rhythm of mean a rte ria l pressure during
angiotensin I I
Day MAP mmHg Change in MAP
7 9 p.m. 104.6
8 9 a.m. 110.6
9 p.m. 100.2
+ 6 .0  
-10 .4  
+ 8.9
9 9 a.m. 109.1
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
9 p.m. 126.1
10 9 a.m. 144*3
9 p.m. 132.3
11 9 a.m. 152.9
9 p.m. 133.8
12 9 a.m. 152.5
9 p.m. 136.7
13 9 a.m. 152.2
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
9 p.m. 98.9
14 9 a.m. 112.8
9 p.m. 104.8
15 9 a.m. 113.5
*p< 0.05
**p<  0,01
+18.2**
- 12.0
+20.6*
-1 9 .1 *
+18.7*
-15 .8
+15.8**
+13.9 
-  8 .0  
+ 8.7
7 7 .
n.
A fte r this in it ia l pressor e ffec t, angiotensin II had a more marked second 
slow developing pressor action. Together the two effects raised a rte ria l 
pressure gradually by 41 mmHg in 4 days. A s im ilar increase occurred in 4 
days in my two earlier experiments (Chapter 3). During the slow rise in this 
experiment, the diurnal variation of pressure was also increased. I t  was shown 
previously that va riab ility  of a rte ria l pressure increased while sodium balance
remained unchanged.
Thus angiotensin II and saralasin share several properties: both increase
arte ria l pressure slowly and w h ile -th is  is occurring both increase the va riab ility  
and diurnal variation of a rte ria l pressure. Do the three effects of angiotensin II 
have a common mechanism and is that mechanism shared by saralasin?
I suspect tha t the three effects of angiotensin II do have a common
nervous mechanism. Theoretica lly an e ffe c t of saralasin could be related to its 
action as an antagonist of angiotensin II or to an action as a partia l agonist 
m im icing angiotensin II. Angiotensin II, on the other hand, acts only as an 
agonist. The s im ila rity  o f the effects o f the two agents suggests tha t those 
produced by saralasin are agonistic since there is the shared property. I t  is 
hardly like ly  tha t angiotensin II raises blood pressure at night in the ra t as an 
agonist while saralasin produces the same e ffec t by antagonising angiotensin II.
Normal rats infused w ith  dextrose show a small diurnal variation o f 
a rte ria l pressure, being lowest in the early evening and highest in the early 
morning. This has been previously noted in rats (Manthorpe 1973). Man also
has diurnal changes of a rte ria l pressure, blood pressure fa lling  markedly during 
sleep (L it tie r. Honour, C arter and Sleight 1975; M illa r-C ra ig , Bishop and 
R afte r y 1978). Since rats sleep fo r most of the day and become active at
night, the fa ll in pressure during the day could be a result of sleep. I have
noted on several occasions that blood pressure fa lls  in the ra t during the day
when i t  sleeps rising when i t  wakes. Several reasons have been suggested fo r
78 .
the fa ll in a rte ria l pressure during sleep in man (L itt le r  et al 1975). The most 
like ly , in my view, is that a reduction in sympathetic outflow  leads to a 
reduction in peripheral resistance (Khatri and Freis 1969; Bristow, Honour, 
P ickering and Sleight 1969), increased baroreflex sensitiv ity also contributing 
(Smyth, Sleight and Pickering 1969). Thus, in the ra t the fa ll in a rte ria l 
pressure during the day may be the result of a reduction in sympathetic outflow  
and the rise at night a result of increased sympathetic outflow . I f  th is is
true, the extent to which saralasin and angiotensin II raise blood pressure is 
greatest when sympathetic a c tiv ity  is highest, during the night. They may 
achieve this by enhancing transmission in the sympathetic nervous system, (but 
the assumption must then be tha t the more a c tiv ity  there is, the greater w ill be 
the enhancement). I t  is known tha t angiotensin II enhances sympathetic a c tiv ity  
by a presynaptic stim ulant e ffec t (Westfall 1977) and recent work by Wilcox, 
Lewis, Sever and Peart (1981) suggests tha t one part of the renal 
vasoconstriction which occurs w ith  saralasin is mediated by renal nerves.
Our experiment also has implications for studies in which saralasin is 
used to test mechanisms of action o f angiotensin II. As noted, the acute 
agonist e ffec t of saralasin somewhat compromises interpre ta tion o f experiments 
testing the role of angiotensin II by short-term  infusions of saralasin (Bumpus 
and Khosla 1977; Fagard, Amery and L ijner 1981). My present experiment 
suggests tha t the slow rise of pressure and increased diurnal variation may also 
compromise experiments in which saralasin is given longterm . The tim ing of
experiments is c learly im portant, since in the normal ra t, saralasin infused at
n ight produces a d iffe ren t e ffe c t from  saralasin infused during the day. I shall 
consider the implications of this la te r.
The original purpose of this part of my study was to  resolve the 
d iffe ren t responses in two experiments in which saralasin was infused fo r 12
hours into renal hypertensive rats (Riegger et al 1977; Bing et al, 1981), The 
findings in normal rats were unexpected and interesting in themselves. I have
7 9 .
described them in a b rie f report (Brown and Lever 1981) and w ill shortly submit 
a fu ll paper. Meanwhile I have not completed the study of renal hypertension: 
some prelim inary results are given below.
4.6 EXPERIMENT 5
EFFECT OF PROLONGED SARALASIN INFUSION ON ARTERIAL PRESSURE IN
FOUR RENAL HYPERTENSIVE RATS.
4.6:1 Methods
Rats were made hypertensive by the application, under ether anaesthesia, 
of a silver c lip  (2.8) to the le f t  renal artery, the righ t kidney being le f t  in situ . 
35-60 days a fte r application o f the c lip , catheters were implanted into the 
abdominal aorta and IVC and rats were allowed to recover in ordinary ra t cages 
(Figures 4.6)
They were placed in metabolic cages on the second postoperative day 
(day 3) fo r 3 days fo r acclim atization and on day 6 were connected to the 
spring and balance, remaining conscious during the connection. They were 
infused w ith  saralasin as described previously fo r normal rats (4.2:1). Infusions 
of saralasin were begun at 10.00 a.m. in 3 rats (m ild ly hypertensive) and at 9.00 
a.m. on one occasion and at 9.00 p.m. on another in one severely hypertensive 
ra t. MAP was recorded continuously from  day 7 un til the end o f the 
experiment in these four animals. Traces were analysed as before,
4.6:2 Results
1) M ild ly  hypertensive rats As in normal rats,, infusion of
saralasin in three m ild ly hypertensive rats raised a rte ria l pressure acutely from  
a mean level of 132.3 + 2.1 mmHg to 158.3 + 4.4 mmHg w ith in  3 minutes of 
starting infusion. Pressure then fe ll to pre-infusion levels w ith in  5 minutes. 
A fte r  this transitional increase, MAP remained at pre-infusion levels un til about
10.00 p.m. when it  began to rise progressively as in the control rats from  a 
level o f 135 + 0.8 mmHg, the day before saralasin, to 150.4 + 1,2 mmHg on the 
4th day (Figure 4.7). There was a slight increase in diurnal variation of
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pressure during saralasin, but as fa r as could be judged in 3 animals this was 
not as marked as in normal rats receiving saralasin. On returning to  dextrose, 
MAP did not fa ll to pre-infusion levels un til at least one day la te r. D iurnal 
variation during this second control dextrose period was markedly increased.
2) Severely hypertensive ra t. One severely hypertensive ra t was
infused, as described above, except tha t saralasin was infused fo r two 4-day 
periods, one starting in the morning, as in the experiment of Riegger et al 
(1977), the other starting at night, as in the experiment o f Bing et al (1981). 
On stopping the f irs t  saralasin infusion, dextrose was infused fo r 5 days, instead 
of 2, to perm it recovery. A second infusion o f saralasin was begun on day 18 
and was carried out as before,
Saralasin begun at night caused a rapid fa ll o f a rte ria l pressure (Figure 
4.8). Mean a rte ria l pressure before saralasin was 177 mmHg. T h irty  minutes 
la te r i t  was 149 mmHg and 90 minutes la te r i t  was 127 mmHg. Thereafter i t  
rose progressively over the 4-day period of saralasin infusion, but as in the 
control experiment, there was a diurnal variation o f pressure. This diurnal 
variation was also apparent in the control period.
A d iffe ren t pattern emerged when saralasin was begun in the morning. 
Mean a rte ria l pressure fe ll gradually over a 10 hour period (Figure 4.9). 
Before saralasin i t  was 185 mmHg; 10,5 hours la te r i t  was 127 mmHg. 
Thereafter i t  rose progressively as before (Figure 4.8). Figure 4.9 compares the 
tim e course of the decrease in pressure during the f irs t  10 hours o f saralasin 
infusion starting  at night or in the morning.
4.7 COMMENT
No firm  conclusions can be drawn from  this small study. I include i t  
here partly  to show that it  is possible, technically, to  infuse renal hypertensive 
rats w ith  saralasin fo r 4 days, measuring arte ria l pressure continuously. Also 
the findings in the severely hypertensive ra t would be interesting and im portant 
i f  confirmed in a group o f 6 more rats.
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No conclusions can be drawn from  the study o f 3 m ild ly  hypertensive
rats. Their hypertension was too m ild fo r comparison w ith  earlier studies. 
These rats did show a slow pressor response w ith  increased diurnal rhythm
during saralasin infusion, although neither e ffects were as marked as in the 
control rats. One severely hypertensive ra t showed a d iffe re n t type o f response 
depending on whether the infusion was begun at night or in the morning (though
I have not excluded a d ifference resulting from  the sequence in which infusions
were given). A fte r  the abrupt fa ll in blood pressure w ith  the f ir s t  infusion 
beginning at night, there was l i t t le  change of blood pressure fo r  the fo llow ing 12 
hours as in the experiment o f Bing et al (1981) where infusions were given at 
night. However, when the infusion was given during the day (Figure 4.9) blood 
pressure fe ll gradually as in the study of Riegger e t al (1977) where infusions 
were also given during the day. U n til more experiments are done, I cannot 
a ttribu te  the difference between experiments to the fa c t tha t saralasin was 
given by day in one and by night in the other. I t  remains a possibility. 
Meanwhile, my finding of a slow pressor response w ith  saralasin, probably 
agonist in nature, raises another problem of in terpre ta tion: blood pressure may
fa ll gradually in hypertensive rats, but not in normal rats infused w ith  saralasin 
either because the antagonist action is greater or the agonist action is less in 
the hypertensive animals. That there was an agonist e ffe c t in the contro l group 
o f normal rats given saralasin by Riegger e t al (1977) is suggested here by the 
fa ll in pressure during the day in normal rats compared w ith  the fa ilu re  of 
blood pressure to fa ll in normal rats infused w ith  saralasin by day (Figure 4.2).
For all these reasons, I am re luctant to place too much reliance on 
inte rpre ta tion  o f the role of renin and angiotensin assessed by prolonged infusion 
of saralasin. I shall complete experiment 5 and repeat the experiment using a 
new renin inh ib itor as described below.
CHAPTER 5
A  NEW IN H IB ITO R  OF R E N IN : P R E LIM IN A R Y  RESULTS IN  THE R A T .
5.1 INTRODUCTION
Problems w ith  saralasin as an agent fo r testing physiological and 
pathological roles of angiotensin II has led to  a hunt fo r be tte r agents blocking 
the renin angiotensin system. Angiotensin I converting enzyme inhibitors have 
been studied (Tree and Morton 1980) but the ir potential in teraction w ith  the 
ka llikre in  system (Thurston and Swales 1978) also clouds in te rpre ta tion  of the ir 
e ffects. A ttention  has therefore turned to renin inhibitors which have none of 
the agonist actions of saralasin or the kinin potentiation o f converting enzyme 
inhibitors. The idea tha t com petitive inhibitors of renin, made by synthesising 
substrate analogues, could inh ib it the system is not new (Skeggs, Lentz, Kahn 
and Hochstrasser 1968), but they have not, as yet, been o f su ffic ien t potency 
and so lub ility  fo r in vivo studies (Haber and Burton, 1979). The synthesis o f a 
new peptide renin inh ib ito r, H77, (Szelke, Leckie, Tree, Brown, Grant, H a lle tt, 
Hughes, Jones and Lever, 1981) w ith  a greater a ffin ity  fo r renin and increased 
so lub ility  was opportune.
The inh ib ito r was tested in v itro  by Dr Brenda Leckie. Figure 5.1 
shows inhib ition curves fo r one experiment in which dilutions o f H77 were tested 
against human, dog and ra t plasma in the same batch o f assays. The e ffic iency 
o f H77 against the renin in dog plasma was greater than against human renin, 
the inh ib itory constant being about 0,3 pM fo r dog renin as against Ip M  in 
human. The inh ib itory constant fo r the reaction o f ra t renin w ith  its  
substrate was around 0.6 pM, Thus, in v itro , H77 was most e ffec tive  in dog 
plasma. Dr Malcolm Tree infused the inh ib itor into sodium depleted dogs. I t  
markedly reduced a rte ria l pressure and plasma concentrations of angiotensin I 
and II when given at rates of 0.1 mg/kg/hour and higher (Szelke et al 1981).
My object in this prelim inary study was to determ ine whether the
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inh ib itor was also e ffec tive  in the ra t in vivo. Higher doses were tested as
the in v itro  data suggested tha t these m ight be needed.
5.2 EXPERIMENT 6
EFFECT OF H77 IN VIVO IN THE RAT
5,2:1 H.77 infusions in normal rats.
Four rats were studied. A o rtic  and IVC catheters were implanted and 
a fte r recovery and acclim atization, rats were connected to the spring and 
balance system on day 6. Each ra t then had three d iffe re n t intravenous 
infusions. These were given in random order on days 7,11 and 15. For one of 
these infusions (part 1 of the experiment, Figure 5.2), 5% dextrose was given at 
1 m l/hour fo r 2 hours, mean a rte ria l pressure being recorded continuously. 
A fte r 1 and 2 hours, 0.5 ml a rte ria l blood samples were taken fo r estimation of 
plasma angiotensin II concentration. Parts 2 and 3 of the experiment were 
carried out in the same way except that H77 at 1 m g/kg/h and at 10 mg/kg/h 
respectively were infused during the second half o f the experiment (Figure 5.2). 
Samples fo r plasma angiotensin II measurement were taken as before. The order 
o f the experiment was as fo llows: Rat 1 -  part 1, part 2 then part 3; Rat 2 -
part 2, part 3 then part 1; Rats 3 and 4 -  part 3, part 1, part 2.
Mean a rte ria l pressure was recorded continuously. The analysis was 
based on values at 5 minute intervals during the 2 hour infusion period.
Results.
H77 infused at 1 and 10 mg/kg/h had no s ign ificant e ffe c t on a rte ria l 
pressure (Figure 5.3). The control infusion of dextrose was also w ithout e ffec t.
Plasma angiotensin concentration did not increase during the infusion of 
dextrose. Mean values fo r the 4 rats during the contro l period (Sample I) on 
the 7th, 11th and 15th days were 45.6 + 5.3, 37.3 + 1.9, 39.3 + 1.4 pg/m l. 
H77 infused at 1 m g/kg/h and at 10 mg/kg/h had no e ffe c t on plasma 
angiotensin II concentration except possibly in one ra t in which angiotensin II 
levels decreased from  42.3 pg/ml to 26.9 pg/m l (Figure 5.4).
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5% Dextrose I 5% Dextrose
1
P art 2
5% Dextrose H77 : 1 m g/kg /h ou r
J
P art 3
5% Dextrose H77 : lO m g/kg/hour
t
0. 5ml a rte ria l sample
Dextrose and H77 infused at 1m l/hour
Figure 5. 2 Experimental protocol
eu
g
CQ<D
U
A
d
(D
u
8
o
120 ~  
100 -
80- 
120
100 .
80' 
120
100 -
80-
Part 1
Dextrose
;
t
“C-O'
t
P art 2
Dextrose H77 : Im g /k g /h o u r
i J L L i
t
Part 3
Dextrose H77 : lO m g/kg /hour
A rte r ia l Sample
T ~
20
” T “
40
“T “
8060
T im e (mins)
100
"T—  
120
Figure 5. 3 Mean a rte ria l pressure during infusion of H77
Dextrose
a
'bB
A
üCO
ü
H
.S
CQ
g
bJD
§
a
CQ
A
100 .
50
A-
t.
H77
Im g /k g /h
H77
lO rag /kg /h
•A
j  t j  1 i
1st 2nd 1st 2nd 1st 2nd
Sample Sample Sample
Figure 5 .4  Plasm a angiotensinI I  levels before and after 
infusion of H77
0 4  .
5.2:2 H77 infusions in renal hypertensive rats.
Two rats were studied, one received H77 at 1 m g/kg/h, the top dose 
infused in the dog. The other received dextrose as a control. Fo rty  to  50 days 
prior to the s ta rt of the experiment, a 0.008" silver c lip  was applied to  the le f t  
renal arte ry, the righ t kidney was untouched (2,8). A o rtic  and IVC catheters 
were implanted 41 days a fte r the application of the clip  and rats were allowed 
the usual period of recovery and acclim atization before being connected to  the 
spring balance system (3,2:1). The experiment began on day 7, 5% detrose was 
infused at 2.4 mls/24 hours fo r 2 days, then H77 at 1 m g/kg/h fo r 2 days and 
fin a lly  dextrose fo r a fu rthe r 2 days. The control ra t received dextrose 
throughout. A rte ria l samples fo r estimation of plasma angiotensin II
concentration were taken on day 7 and day 10 (Figure 5.5), Mean a rte ria l 
pressure was recorded continuously and analysed as before (4,2:1),
Results Figure 5.6 shows mean a rte ria l pressure
during prolonged dextrose and prolonged H77 infusion in renal hypertensive rats, 
MAP showed l it t le  change during H77 infusion compared w ith  the control 
dextrose infused period. The control ra t infused w ith  dextrose, however, 
showed an increase in pressure over the 6 day period, MAP on day 7 was 131.8 
+ 1.2 mmHg and on day 12 was 151.5 + 0.8 mmHg.
Plasma angiotensin II levels fe ll from  71.1 pg/ml to 49,9 pg/m l during 
infusion of H77. The angiotensin II levels in the dextrose infused ra ts , however, 
increased slightly from  44.2 pg/ml to  51.9 pg/ml.
I t  was decided to test higher rates o f infusion. One renal hypertensive 
ra t was prepared as before. On day 7, dextrose was infused fo r 1 m l/h  fo r one 
hour and then H77 at 100 mg/kg/h fo r one hour. Mean a rte ria l pressure was 
recorded continuously. H77 raised a rte ria l pressure by 41 mmHg, but the 
e ffe c t lasted fo r 6 minutes only. Blood pressure then fe ll.  Although the 
infusion was stopped a fte r 10 minutes, pressure continued to fa ll and the ra t 
died 3 minutes la te r.
[:
!
Implantation 
of
Appllcation^^^^®^®^® Recovery Acclimatisation 
of clip to cage
0. 5ml
arte ria l
sample
0. 5ml
arte ria l
sample
r
1 Dextrose H77 Dextrose
Connection of spring
r “
■40
Days
Figure 5.5 Experimental protocol
T ”
10
n
12
faD 03œ0
1
Q
CM
05
00
-  C“
-  CD
L_ lO
"c^
î
g4->
g
gfn
.S
I  
i
t -  
t ~
K  
tO
§
CD in
ITS
bû
.S
a I
CD
Ico
CD
A
73
• p-l
i ?
§
CD
g
CO
LD
CD
&
Fq
en
o
CM
CM
O
C O
O
o
CM
O
CD
O
CM
T—H
Shwiui ajnssajd; u-ean
00 .
5.5 COMMENT.
In v itro  testing of H77 showed that i t  is a more e ffec tive  antagonist o f
dog renin than o f human or ra t renin. Dr Tree’s experiment in the conscious
dog and my own experiment in the conscious ra t confirm  this. The fa ilu re  of 
H77 to reduce angiotensin II and blood pressure in the ra t makes i t  less like ly
tha t the positive result in the dog is a non-specific e ffe c t o f H.77 unrelated to
its  action as an inh ib itor of renin.
My studies also suggest tha t the inh ib itor is ine ffec tive  in the re t a t a 
dose which is not tox ic , but possibly tox ic  at doses which are more like ly  to be 
e ffec tive . F erring L td . have done to x ic ity  tests w ith  H77 in the ra t. The
LD50 fo r intravenously injected inh ib itor is 5 m g/rat. One ra t died in my
experiment. By the tim e of death i t  had received the largest dose, 3.8 mg.
The synthesis of new renin inhibitors is underway and in v itro  tests
already show one o f these to be a more e ffective  inh ib ito r of ra t renin than is 
H77. Thus, there are prospects fo r testing e ffective  inhibitors of renin in 
conscious rats. I t  is im portant tha t this is done, in my view, as the agonist 
action of saralasin and the kinin potentiation of converting enzyme inh ib ito r 
complicates analysis of the highly complex mechanism at work in renal
hypertension (Swales 1979). The new renin inhib itor should be w ithout these
second effects.
CHAPTER  6 
G EN ER AL DISCUSSION.
In earlier parts of this thesis I have discussed the differences between 
the fast and slow pressor e ffects of angiotensin II and have compared plasma 
angiotensin II levels during the two e ffects, I have discussed the diurnal e ffects 
of saralasin and angiotensin II and the in v itro  and in vivo testing of a new 
renin inh ib ito r, I shall consider here in a more general discussion the mechanism 
of the slow pressor e ffe c t o f angiotensin II and its possible roles in the
pathogenesis of renal hypertension and in the regulation o f a rte ria l pressure.
6,1 SUMMARY OF MAIN FINDINGS.
The studies carried out here have shown tha t angiotensin II when given
in low dose to conscious rats, raises a rte ria l pressure gradually over a 7 day
period. When the duration o f the infusion was increased to  14 days, a rte ria l 
pressure rose fu rthe r. This slow response has been shown in a varie ty of 
species (see pages 29-31 in the Introduction), but in none did i t  develop as 
markedly or as rapidly as in the ra t. Its  magnitude in the ra t a fte r 7 days was
sim ilar to tha t of the maximum direct response, and a fte r 14 days i t  was higher
s til l.  The slow pressor e ffec t developed at a plasma concentration of 
angiotensin II w ith in , or close to, the physiological range and at much lower 
levels than those required to  produce a d irect response o f s im ila r magnitude. 
The diurnal variation o f a rte ria l pressure also became more marked during 
prolonged angiotensin infusion and the va riab ility  of pressure increased.
Saralasin also produced a slow rise o f pressure w ith  increased diurnal
variation and va riab ility  of pressure. Food and water intake and sodium balance 
remained unchanged by prolonged saralasin and angiotensin infusions. These 
findings, together w ith  the structura l s im ila rities between angiotensin II and 
saralasin, suggest tha t both peptides are acting by a s im ila r mechanism to  raise 
a rte ria l pressure.
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6.2 POSSIBLE MECHANISMS OF THE SLOW PRESSOR EFFECT OF
ANGIOTENSIN II.
A number of suggestions have been made as to the mechanism of the 
slow pressor e ffe c t of angiotensin II (Brown et al 1977). Some are discussed 
below.
6.2:1 Action of angiotensin II on the nervous system.
I t  is well know tha t angiotensin II has an action on both the central and 
peripheral nervous system (Yu and Dickinson, 1965; Lowe and Scroop 1969; 
Ferrario et al 1972; W estfall 1977) and there has been much to suggest tha t the 
nervous system participates in the slow e ffe c t. Drugs which in te rfe re  w ith  
nervous transmission prevent or attenuate the rise of pressure (McCubbin et al 
1965; Yu and Dickinson 1971). Resetting of baroreceptors is partly responsible 
fo r the early rise o f pressure produced by low dose angiotensin II in the dog 
(Cowley and DeClue 1976) and there is evidence tha t the baroreceptor re flex  is 
modulated by central adm inistration of angiotensin II (Fukiyama 1973, Goldstein 
et al 1974; Marker et al 1980). Further evidence fo r partic ipation o f the 
nervous system comes in this study from  the increase in va riab ility  of pressure 
and increased a c tiv ity  o f the rats in this study. Dogs in the study o f McCubbin 
et al (1965) also showed increased va riab ility  of pressure. Increased diurnal 
changes of pressure during angiotensin II infusion may also be indicative o f an 
action on the nervous system as described earlier (Chapter 4). Angiotensin II 
could thus be acting either centra lly  or peripherally or at both sites; to  raise 
a rte ria l pressure. In the ra t periventricular structures surrounding the 3rd 
ventric le  have been shown to mediate the central component of the pressor 
action of blood borne angiotensin II (Fink et al 1980). This area is also a 
crucial site fo r the integration of c ircu la tory, hormonal and behavioural 
responses involved in maintaining salt and water homeostasis in the ra t (Buggy 
and Johnson 1977; Johnson and Buggy 1978; Brody, Fink, Buggy, Haywood, 
Gordon and Johnson 1978). The anteroventral 3rd ventric le  (AV3V) region also
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encompasses a varie ty of periventricu lar structures in the anterior hypothalamic 
pre-optic region of the forebrain, including the organum vasculosum of the
lamina term inalis (OVLT), a highly vascularised area in which the blood brain 
barrier is re la tive ly  defic ient. This site would be an ideal location of neural 
elements sensitive to concentrations o f angiotensin in the blood perfusing the 
brain. I t  is, therefore, possible tha t angiotensin II is acting on such a site to 
produce its  slow pressor e ffe c t. I discussed earlier the evidence tha t the area
postrema mediates the central pressor e ffec t of angiotensin II in other
mammals,
6.2:2 An e ffec t on sa lt and water excretion.
Angiotensin II alters urinary excretion of sodium and water (Brown and 
Peart 1962) and thus by acting d irec tly  or through aldosterone, could cause 
sodium and hence water retention, thereby raising blood pressure (Brown et al 
1977). I did not, however, find sodium retention in rats during the slow rise, 
but the case fo r sodium retention should probably not be dismissed on this 
evidence as there are major d ifficu ltie s  in calculating cumulative balance
properly in the ra t (Mohring and Mohring 1972). Although the differences were 
not s ignificant, rats receiving angiotensin II did have a greater cumulative 
balance than the control rats (Chapter 3). Work in other species has been 
conflic ting . In man (Ames et al 1965; Oelkers et al 1978) and in the dog 
(Urquhart, Davis and Higgins 1963) prolonged angiotensin II infusion did produce 
sodium retention. In rabbit (Dickinson and Yu 1967), however, there was no 
evidence fo r a causative role fo r sodium. Sodium status is obviously im portant, 
however, since the pressor response to angiotensin II is increased during sodium 
retention (Slack and Ledingham 1976) and the slow rise in pressure in dogs is 
prevented by dietary salt res tric tion  (Cowley and McCaa 1976). Also the rate 
and magnitude of the rise of pressure during prolonged angiotensin II infusion is 
greatly increased by increasing d ietary sodium (Cowley and McCaa 1976, DeClue, 
Guyton, Cowley, Coleman, Norman and McCaa 1978).
Whether angiotensin II acts by stim ulating aldosterone is also unclear. 
The balance of evidence suggests tha t during chronic angiotensin II infusion, the 
increase of aldosterone is not persistent or marked, and tha t a sodium retaining 
e ffe c t of angiotensin II is more like ly  to be renal than adrenal (DeClue et al 
1976, H all et ai 1979, Bean et al 1979). A t low doses angiotensin II promotes 
renal retention of salt and water, and this e ffec t is compensated fo r by the 
accompanying rise of a rte ria l pressure which promotes diuresis and natriuresis. 
In this study, although there was no early sodium retention, there was sodium 
loss (insignificant s ta tis tica lly ) towards the end of the 7 day infusion which was 
probably a result of the high level of mean arte ria l pressure. I shall pursue the 
possibility that longer infusions result in a higher a rte ria l pressure w ith  greater 
sodium depletion and perhaps malignant phase hypertension.
I t  has been proposed that sodium and water retention results in 
expansion of plasma and extrace llu lar flu id  volume which raises cardiac output 
and, because of overperfusion of tissues, produces an autoregulatory 
vasoconstriction w ith  decrease of cardiac output, hypertension then being 
maintained by vasoconstriction (Guyton 1969; Ledingham 1971). Evidence fo r 
an in it ia l increase in cardiac output, however, is not available. In fa c t In the 
dog (Cowley and DeClue 1976), cardiac output was decreased in it ia lly  and then 
increased during the 4th-5th day o f prolonged low-dose angiotensin II infusion. 
There could be a contribution from  autoregulation therefore, as the authors say, 
but i t  is not the whole explanation.
Thus, sodium status may modify the rate of rise o f pressure, but th is is 
a d iffe ren t issue from  sodium retention being the prim ary cause of the rise of 
pressure. On balance, I favour a primary role fo r the nervous system. I t  is 
interesting then that the AV3V region, the area involved in the centra l pressor 
action of angiotensin II, is also involved in water and sa lt homeostasis (Johnson 
and Buggy 1978).
6.2:3 Structural changes during the slow e ffec t.
The rise of pressure during prolonged infusion of angiotensin II could 
produce structu ra l changes in the small resistance vessels which would help to  
maintain the hypertension. Folkow (1971) has suggested tha t the small 
resistance vessels, respond to raised pressure by increasing w all thickness and 
thus wall/lum en ra tio , thus raising resistance to flow  at maximum dila ta tion and 
increasing the response to  vasoconstrictor agents. Koletsky, R ivera-Velez and 
Pritchard (1966) infused angiotensin into rats fo r 12 hours per 24 hours fo r 5 
days and showed thickened arterioles w ith  narrowed lumens. The ra te  of 
infusion in tha t study, however, was 100 ng/kg/m in, five  times the dose used in 
my experiment.
Changes in the vessels may explain the enhanced response to  a pressor 
infusion of angiotensin II on stopping prolonged angiotensin II infusion. Tobian, 
Janecek, Tomboulian and Ferre ira (1961) suggested that increased sodium in 
vascular tissue could heighten the response to vasoconstrictor agents. I t  is of 
interest, therefore, tha t prolonged angiotensin II infusion increased vascular 
sodium (V illam il, Nachev and Kleeman 1970).
6.2:4 A combination of mechanisms.
I t  is certa in ly  not clear whether a combination of mechanisms or a 
single mechanism is responsible fo r the slowly developing pressor action of 
angiotensin TI. The mechanisms outlined above are not m utually exclusive: 
angiotensin II acting through the nervous system could a ffe c t salt and w ater 
balance and changes of sodium and water could modify the rise of pressure. 
Also changes in sodium status could a ffec t wall/lumen ra tio  and hence vascular 
tone.
I t  is clear that fu rthe r work must be done to elucidate the mechanism 
of the slow pressor e ffec t of angiotensin II. I hope to test the possibility tha t 
the nervous system is involved by using sympathetic nervous blocking agents. I t  
would also be o f interesting to try  to produce the slow rise of pressure 
fo llow ing ablation of the AV3V region. I shall, w ith  D r Stephen Ball, measure
plasma noradrenaline during the slow rise of pressure, seeking evidence of 
increased transm itte r release. I f  noradrenaline rises, I would be particu larly  
interested to see i f  propranolol prevents the slow rise of a rte ria l pressure.
6.3 ROLE OF THE SLOW PRESSOR EFFECT OF ANGIOTENSIN II 
IN THE PATHOGENESIS OF RENAL HYPERTENSION.
There is considerable controversy about the mechanism by which 
sustained blood pressure elevation follows renal artery constriction. In the early 
phase of Goldblatt two-kidney one c lip  hypertension, plasma levels of renin and 
angiotensin II are raised su ffic ie n tly  to  account fo r the hypertension by d irect 
vasoconstriction (Caravaggi et al 1976) and renin-angiotensin blockade lowers 
blood pressure to normal at this tim e (Pals et al 1971b; M ille r, Samuels, Haber 
and Barger 1975; Coleman and Guyton 1975; Masaki et al 1977; Freeman et 
al 1977). In the la te r stages, however, plasma levels of renin and angiotensin II 
decline and are insuffic ient to raise blood pressure by d irect vasoconstriction 
alone (Blanchi et al 1972; Brown et al 1977b). The mechanism responsible fo r 
maintaining the hypertension at this stage is unclear. Dickinson and Lawrence 
(1963) were the f irs t to suggest tha t the slow pressor e ffe c t m ight be im portant 
in the pathogenesis of chronic renal hypertension.
In the experiments described here, dose-response studies testing the 
d irect pressor response of angiotensin II during the slow rise o f pressure showed 
an upward sh ift in the curve re la ting a rte ria l pressure and rate of angiotensin 
infusion, a given ra te maintaining a higher pressure. Bean et al (1979) 
demonstrated an upward sh ift in the curve relating a rte ria l pressure and plasma 
angiotensin II concentration during the slow pressor e ffe c t in the dog. Thus, a 
constant increase in plasma concentration of angiotensin II maintained a 
progressively higher level of pressure. Data in a patient w ith  renin-secreting 
tumour also suggests this (Brown, Fraser, Lever, Morton, Robertson, Tree, Bell, 
Davidson and Ruthven, 1973), A rte ria l pressure and plasma concentrations o f 
angiotensin II are both increased in the disease, but a rte ria l pressure is higher
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than can be explained by the d irect pressor action of angiotensin II. This state 
exists in chronic renal hypertension where blood pressure is higher fo r a given 
level o f angiotensin II than in normal subjects in whom pressure is raised 
acutely by infusion of angiotensin II (Brown et al 1976b, 1977). I t  does not,
however, fo llow  tha t angiotensin II has produced the state in renal hypertension,
although i t  is very like ly  to have done so in renin-secreting tumour. The slow
pressor e ffec t of angiotensin II and a hypertensive disease, renin-secreting
tumour, resulting from  excess of renin and angiotensin thus both produce 
changes sim ilar to those observed in chronic renal hypertension. Although these
findings are compatible w ith  a role fo r the slow pressor e ffe c t in chronic renal
hypertension, they do not establish it .
Work w ith  inhibitors of the renin-angiotensin system to  assess the ro le  of
angiotensin II in the pathogenesis of chronic renal hypertension has been 
conflic ting . Many workers have shown tha t renin-angiotensin blockade has l i t t le  
or no e ffec t on a rte ria l pressure in these la ter stages o f the hypertension
(Thurston and Swales 1974; Gavras, Brunner, Thurston, Laragh 1975, Sen, 
Smeby, Bumpus, Tucotte 1979; Bing et al 1981) while others have produced a 
progressive fa ll in blood pressure w ith  prolonged infusion o f inhibitors (Riegger 
et al 1977; Bengis and Coleman 1979). The inhibitors used, however, do possess 
additional properties and therefore make interpretation o f results d if f ic u lt . To
my mind, use of inhibitors in these experiments has neither proved nor disproved
a role fo r angiotensin II in the pathogenesis of chronic renal hypertension.
However, Thurston, Bing and Swales (1980) have recently reported an experiment 
in which a renal artery clip  was removed from  a hypertensive ra t during 
blockade of the renin-angiotensin system. Blood pressure fe ll as in unblocked 
animals which strongly suggests tha t changes in the renin mechanism are not 
responsible fo r the fa ll of pressure when renal hypertension is reversed. I t  is 
my intention to repeat the experiment o f Riegger et al (1977) using the new 
renin inh ib itor which is being developed.
I f  the mechanism of the slow pressor e ffec t o f angiotensin II is a 
nervous one and the e ffe c t does play a role in renovascular hypertension, one 
would expect some evidence fo r the partic ipation of the nervous system in renal 
hypertension. Indeed there is considerable evidence fo r its  involvement. The 
development of a number of forms of experimental hypertension including renal 
hypertension produced by perinephritis can be prevented by the destruction of 
central catecholamine neurones (Chalmers, Dollery, Lewis and Reid 1974).
In the ra t, the centra lly mediated pressor a c tiv ity  o f angiotensin II is 
dependent upon activation of angiotensin receptors located in the ventricu lar 
system in the pre-optic hypothalamic region. The in te g rity  of this region, the 
AV3V region, is essential fo r the development and maintenance of hypertension 
in a number of models (Brody et al 1978). I f  the AV3V region is im portant in 
the mechanism of the slow pressor e ffec t of angiotensin II, as discussed earlier, 
the findings discussed here suggest, i f  very ind irectly , th a t the slow response 
may be involved in the pathogenesis of renal hypertension.
There was some evidence, however, suggesting th a t the mechanism of 
the slow pressor e ffec t involved salt and water re ten tion  since sodium 
res tric tion  prevented the rise o f pressure in the dog (Cowley and McCaa 1976). 
The fa c t tha t d ietary salt restric tion  has l i t t le  e ffe c t on a rte ria l pressure in 
experimental renovascular hypertension, on the other hand, tends to  discount a 
ro le  fo r the slow pressor e ffec t of angiotensin II (Swales 1979).
In conclusion, the importance of the slow pressor e ffe c t of angiotensin II 
in the pathogenesis o f chronic renal hypertension is very unclear. Some 
observations favour a role, but equally others are against i t .  Work w ith  new 
renin inhibitors may be enlightening ,
6.4 A PHYSIOLOGICAL ROLE FOR THE SLOW PRESSOR EFFECT OF
ANGIOTENSIN II
As noted earlier, there are many ways in which angiotensin II m ight act 
physiologically: as a local tissue hormone in the extravascular spaces o f the
kidney, brain and blood vessel wall or as a blood borne hormone. I t  is generally 
agreed tha t blood borne angiotensin II may influence a rte ria l pressure p rim arily  
by its d irect vasoconstrictor action, tha t it  may a lte r urinary sodium excretion 
by a d irect renal action and tha t i t  stimulates aldosterone. What has not been 
considered so often is the possibility tha t by its slow pressor action, angiotensin
II is also an im portant longterm regulator of a rte ria l pressure.
The slow e ffe c t develops w ith  a 4-6 fo ld  increase in plasma 
concentration. A comparable d irect vasoconstrictor e ffe c t requires a 32-fold 
increase. Higher levels o f angiotensin II were obviously required fo r an e ffe c t 
on sodium excretion and drinking than those found during the slow response in 
the ra t. In the dog, a 2-fo ld increase in plasma angiotensin II produced a 22 
mmHg rise of pressure over a 2 week period w ith  only an in it ia l transient
e ffe c t on aldosterone. These results suggest that thresholds fo r  the dipsogenic, 
e lectro ly te , steroidogenic and d irect pressor effects of angiotensin II are higher 
than that fo r the slow pressor e ffe c t. I t  follows th a t the most like ly
consequence of a small rise o f plasma angiotensin II w ith in  the physiological 
range is a slow rise o f a rte ria l pressure. I t  remains to  be seen whether small 
increases of angiotensin II can be su ffic ie n tly  sustained.
My thesis began w ith  a description of the discovery o f renin by 
Tigerstedt and Bergman in 1898. They also proposed tha t renin was a blood
borne agent released from  the kidney, producing an e ffec t at a distance. This
was one of the earliest descriptions of a hormone. Less w e ll known and more
relevant to the slow pressor e ffe c t was the ir idea on the mechanism by which
renin raises blood pressure.
"The experiments reported here indicated tha t the kidney (also) secretes a
substance which affects vascular tone, probably via the peripheral
vasomotor centres ....... . I t  is possible, fo r example, th a t in renal
disease, this substance is produced in larger quantities or is metabolized 
more slowly and leads to a permanent increase in vascular resistance,"
Tigerstedt and Bergman (1898)
(translated by Axel Ph illip i).
APPEN D IX  1
CONSTRUCTION OF C A R O TID  AN D  JU G U LA R  CATHETERS.
The form o f the three catheters -  carotid type 1 and type 2 and
jugular catheter - is illustra ted  in Figure 1. Carotid catheter type 1 consisted
of a 10 cm length o f tygon (Table 1) and 3.5 cm length of polythene (Table 1). 
One end of the tygon tubing was enlarged by stretching over a number 21 gauge 
hypodermic needle which had been filed  smooth. The polythene was then 
inserted 1 cm into the tygon tubing (Figure 1),
Carotid catheter type 2, consisting o f 10 cm o f N T/2 transparent vinyl
tubing (Table 1) and 3.5 cm oF polythene was constructed in an identical way to  
carotid type 1 catheter, the polythene tubing being inserted 1 cm into the NT/2 
tubing.
The jugular vein catheter consisted of a 13 cm length of polythene 
tubing (Table 1 and Figure 1).
Carotid Catheter T ype 1 
3 .5cm
Polythene tubing (O.SmmOD, 0 .4 ID )
10cm Tygon 
0 .51mm I D , 1 .5 3 0 01 1cm
2 .5cm
lying within the carotid artery
Carotid Catheter T ype 2
Identical to type 1 except materials are different A 10cm length 
of transparent vinyl tubing was used instead of tygon and 3.5 cm 
length of polythene tubing (0. 38mmID, 1.09mm CD)
Jugular Catheter
13cm
^ --------- - ----------------------------------- —- -------->.
.............. 7\
U--------------->i
.... - u
2 .5cm r
lying within jugular vein polythene tubing
0. 8mmOD, 0 .4  m m ID  
Figure 1 Carotid artery  and jugular vein catheters
Table 1 M aterials  used in construction of carotid and jugular catheters.
CAROTID TYPE 1 CATHETER
10 cm length of tygon polythene: internal diameter 0,5 mm; outside
diameter 1.53 mm. Norton Plastics, Akron, Ohio.
3.5 cm. length of polythene tubing: internal diameter 0.4 mm: outside
diameter 0.8 mm - 800/100/140. Portex L td ., Hythe, Kent, England.
CAROTID TYPE 2 CATHETER
10 cm length of NT/2 transparent vinyl tubing:, in ternal diameter 0.91 
mm, outside diameter 1.52 mm. Portex L td .
3.5 cm length of polythene tubing: internal diameter 0.38 mm; outside 
diameter 1.09 mm -  800/100/120. Portex L td .
JUGULAR VEIN CATHETER.
- 13 cm length of polythene tubing: internal diameter 0.4 mm; outside
diameter 0.8 mm - 800/100/140. Portex L td .
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APPEN D IX  2 CONSTRUCTION OF A O R TIC  CATHETERS.
The catheter consisted o f 4 pieces of polythene A,B,C and D; welded 
together by heating. In addition i t  had 3 anchor points used to  secure the
catheter to the tissues by sutures. Figure 2 shows a catheter and its main
parts and Table 2 lists the materials used in making the catheter. Each part
was prepared separately before assembly.
Preparation of catheter parts before assembly.
Part A. The polythene was threaded over the 35 gauge copper w ire ,
previously siliconed to make the threading easier. The polythene was heated 4 
cm from  one end over a heating coil. When molten it  was removed from  the 
coil and pulled out f irm ly  to  give a th in walled section of tube about 3 cm 
long, as shown in Figure 2. The drawn out tubing was trim m ed to  give a 2.5 
cm length of normal walled tubing before the thin walled portion. This was 
then threaded over the 35 gauge w ire again and heated 2 cm from  the end over 
a sm all soldering iron un til pliable. The tubing was then compressed along the 
w ire to form  a small ridge or flange. The tubing was removed and allowed to 
harden in a ridge. A second ridge was made 0.5 cm from  the f irs t,  as shown 
in Figure 2.
Part C This polythene was heated at one end un til i t  was fla red
(Figure 2.), I t  was then widened over a length of 18 gauge tinned copper w ire, 
stretching i t  su ffic ie n tly  to push i t  over part B.
Part D. One end of the polythene was widened over a length o f 16
gauge copper w ire. As shown in Figure 2., the end was now su ffic ien tly  
expanded to be pushed over parts B and C.
Assembly of the catheter.
Sealing part A to part B. A short length of 35 gauge copper w ire was
inserted inside the 26 gauge needle tubing. The needle tubing was then 
constricted over the w ire so that the la tte r was held f irm ly  and about 1 cm
Heat seals
90° bend here
P art C
Anchor point
Pulled out section
n
I
P art A
Part D
)■ Neck 
Piece
Neck anchor point
P art B
-Anchor point
Figure 2 Aortic catheter
Table 2 Parts of the aortic  catheter
PART A 10 cm length of PE 10 polythene tubing , internal 
diameter 0,28mm; external diameter 0.61mm. Clay 
Adams, Bee ton, Dickinson and Company.
PART B 15 cm length of polythene tubing 800/100/200, internal 
diameter 0.58 mm, external diameter 0.96 mm. Portex 
L td ., Hythe, Kent, England.
PART C 0.5 cm length of polythene tubing 800/100/280, internal 
diameter 0.86 mm, external diameter 1.52 mm. Portex 
L td ,
PART D 5.0 cm length of polythene tubing 800/100/320, internal 
diameter 1.14 mm, external diameter 1.5 mm. Portex L td .
MATERIALS USED IN THE MAKING OF THE CATHETER.
30 cm length o f 35 gauge copper w ire.
Silicone Fluid (MS 555, Hopkin and W illiams L td ., Chadwell 
Heath, Sussex).
20 cm length o f 26 gauge stainless steel tubing.
10 cm length o f tinned copper w ire, 18 gauge
10 cm length of tinned copper w ire, 16 gauge.
projected out of the end of the tubing. Part A was threaded onto the w ire and 
Part B threaded over the needle tubing and about 2 mm of part A. The two 
lengths of polythene were then heat sealed together over a soldering iron. This 
seal forms one end of the anchor point (Figure 2). Part B was then heated 1 
cm from  the f irs t seal until pliable. Both ends were pushed s ligh tly  together to 
form  a small ridge which was compressed over the needle tubing before the 
plastic hardened and formed the other end o f the anchor point (Figure 2).
The neck piece. Part C was pushed, fla red  end f irs t, over
the top of Part B to about 5 cm from th e  end. The widened part D tubing was 
then threaded over part B and onto part C (Figure 2). This jo in was also heat
sealed. The seal and the flange of part C formed the neck anchor point.
Further seals between part B and part D at approximately 1 cm intervals were 
made. The fina l seal was made and cut through w ith  a sharp scalpel to  ensure 
correct sealing.
The 5-bend Part A was bent on a plastic fo rm er,
dipped into boiling water and then set by cooling rapidly under the cold tap. 
The S-bend was such tha t the A-B junction occurred just before the f irs t  bend, 
the th in walled portion of part A occurring just before the second bend (Figure 
2).
A 90 degree bend on the neck piece. A bend was made at the
th ird  heat seal on the neck pièce as shown in Figure 2. The neck piece was 
threaded over a length of 26 gauge needle tubing. The tubing and hence the 
catheter was bent into a -righ t angle, so tha t i t  protruded from  the skin surface 
a t righ t angles when in position. The needle tubing and neck piece were dipped 
into  boiling water and set by cooling in cold water. On removing the needle 
tubing the 90° bend remained.
APPEN D IX  3 CONSTRUCTION OF VENA C A V A L CATH ETER
The vena caval catheter, like the aortic catheter, also consisted o f 4 
pieces of polythene, welded together by heating. The materials used are 
Identica l to those used in the aortic  catheter (Table 2) w ith  one exception, 17 
cm o f polythene tubing was used as part B of the venous catheter instead o f 15 
cm as in the aortic catheter. Figure 3 shows a constructed catheter.
Preparation of catheter parts before assembly.
Straightening part A
10cm of polythene was threaded over the 35 gauge copper w ire , which 
had been siliconised. The tubing was clamped to the w ire at both ends using 
arte ry forceps. The polythene and w ire were dipped into boiling water and then 
rapidly cooled in water. The w ire was removed and the polythene was now 
stra ight.
The remaining parts o f the catheter were prepared as before fo r the 
aortic catheter.
Assembly of the catheter.
The straightened length of polythene (part A) was threaded onto 35 
gauge w ire needle tubing fo rm erly  described in the construction of the aortic  
catheter. Part B was threaded onto the tubing and pushed over part A to  give 
an overlap o f 3-5 mm. The junction was heat sealed. An anchor point was 
formed 2 cm from this seal by heating an area o f the tubing un til a ridge had 
formed
The remaining parts were assembled as fo r the ao rtic  catheter.
The U-bend.
A U-bend was made in the catheter by bending the part o f catheter 
distal to the anchor point on part B round the plastic form er used in the 
construction o f the aortic  catheter and dipping i t  into boiling w ater fo llowed by 
rapid cooling under the cold tap.
Neck
Piece P art D
P art B
Anchor point in - 
R . Psoas Muscle
t  • Heat seals
90° bend here 
Neck anchor point 
P art C
P art A
Figure 3 . Vena caval catheter
i.UJL .
A 90° bend was made on the th ird  seal on the neck piece, as in the 
aortic catheter. Catheters were tested as before.
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